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“After all, as psychiatrists, we have chosen to study the most complex functions of the 
human being’s most intricate organ. The human brain/mind not only self-wires—a 
system far more intricate than the genome can specify in any one-to-one relationship—
but also is the great organizer and compiler of our own existence. It remembers and 
changes in ways that the liver, kidney, or heart can never do. It interfaces between our 
organism and the psychological, social, and cultural world around us to provide the 
structure and meaning of our existence. We have chosen to study and treat the most 
complex of human disorders, the causes of which span the many levels of our biology, 
our psychology, and our social existence. If the common, morbid dysfunctions of the 
human cardiovascular, immune, hormonal, musculoskeletal, and gastrointestinal 
systems, which cause most of the morbidity in our country, are highly multifactorial, 
could we realistically expect anything else from the parallel dysfunctions of our 
mind/brain system?” 
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Abstract  
Background Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous, 
multifactorial and life-spanning neurodevelopmental disorder for which the underlying 
mechanisms and causes are not fully understood. Psychiatric comorbidity is common, 
but there is limited knowledge about sex differences and patterns of comorbidity in 
adults with ADHD. Likewise, ADHD is known to be highly heritable, but little is 
known about sex patterns in the transgenerational recurrence risks of ADHD, both for 
parents and offspring. Gaining more knowledge about these topics will increase the 
understanding of ADHD both from clinical and neurobiological perspectives.  
Aims This thesis is based on three scientific papers with the following main aims; 1) 
investigate potential sex differences in the risk of comorbid psychiatric disorders in 
adults with ADHD compared with adults without; 2) investigate patterns of psychiatric 
comorbidities between adults with ADHD, ASD, both ADHD and ASD, and adults 
without these disorders, and evaluate these patterns in light of available genetic data, 
and 3) investigate the parent-offspring recurrence risk of ADHD by parental and 
offspring sex.  
Material and methods Data from four nation-wide registries were linked and were the 
main basis for all the papers: The Medical Birth Registry of Norway (MBRN), the 
Norwegian Patient Registry (NPR), the Norwegian Prescription Database (NorPD), 
and the National Educational Database (NED). The NPR (2008-2015) and NorPD 
(2004-2015) provided ADHD information. Papers I and II included only adults, born 
1967-1997, and the outcomes were psychiatric disorders (anxiety, depression, bipolar, 
personality, substance use, and schizophrenia spectrum disorder). Effect measures 
were determined by Poisson regression and evaluated both on the absolute and the 
relative scales in all three papers. For paper II, genetic correlations were also calculated 
by linkage disequilibrium score regression, exploiting summary statistics from relevant 
genome-wide association studies. In paper III, all individuals born 1967-2011 and their 
parents were identified using the MBRN, and transgenerational recurrence risks for 
mothers and fathers to offspring were calculated.  Additionally, individuals born 1967-
1968 were followed to 2011 and linked to any own children to evaluate the cumulative 
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reproduction and the age at first childbirth in men and women with and without ADHD. 
Age at first childbirth was then taken into account when re-calculating recurrence risks 
in men born 1967-69 and women born 1970-73.                                                              
Results Adults with ADHD had a 4-9 times higher prevalence of other psychiatric 
disorders than adults without ADHD. Compared to men and women without ADHD, 
the differences in prevalence of anxiety, depression, bipolar and personality disorders 
were significantly larger in women than in men, whereas the prevalence difference of 
schizophrenia and substance use disorder were significantly larger in men than in 
women. When using prevalence ratios, the sex patterns were opposite. Risks differed 
between ADHD and ASD for all psychiatric comorbidities. Risks were highest in 
individuals with ADHD and ADHD+ASD for most comorbidities, both in men and 
women. Genetic correlations supported these patterns. Regarding transgenerational 
recurrence risk of ADHD, mothers with ADHD showed stronger associations with 
offspring ADHD than fathers, and recurrence risks were higher in female offspring 
than in male offspring from either parent. Prevalence of offspring ADHD when both 
parents had ADHD was 41.5% in sons and 25.1% in daughters. Men diagnosed with 
ADHD had lower cumulative reproduction than women with ADHD (75.2% versus 
90.4%, respectively) and were generally older at childbirth. 
Conclusions Psychiatric comorbidities are frequent in adults with ADHD but differ 
significantly between men and women. Adults with ADHD, ASD or the combination, 
have specific patterns of psychiatric comorbidities, and differed by sex. Stronger 
ADHD recurrence risk from mothers than fathers could be due to stronger maternal 
genetic effects, a stronger effect of maternal non-transmitted alleles, maternal health-
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1. Introduction  
Attention-deficit/hyperactivity disorder (ADHD) is a worldwide1, frequent 
neurodevelopmental disorder with childhood-onset, characterized by a persistent, 
trans-situational pattern of inattention and/or hyperactivity-impulsivity that interferes 
with functioning or development2-5. ADHD affects millions of both children and adults 
across the world and is of major public health concern6,7. The estimated worldwide 
prevalence of ADHD is 5-7 % in children and adolescents8-10, and ~2.5% among adults 
1,11.  
ADHD is a condition with large consequences for the affected individual; increased 
risk of lower education12, occupational disability13, somatic14-16 and psychiatric 
disorders17, and premature death18,19. Thus, ADHD seriously affects the productivity, 
life expectancy, and quality of life throughout the lifespan of affected individuals20.  
ADHD symptoms persist into adulthood in about 2/3 of the individuals6,21,22. Further, 
in the last two decades, ADHD has been extensively documented as a condition also in 
adults6,23,24. The question of an idiopathic adult-onset ADHD has been raised after three 
population-based studies reported prevalences from 2.7-10.3%25-27. However, all 
studies had major limitations further described by Franke and colleagues6. 
Inattentiveness is the most persistent symptom into adulthood, whereas hyperactivity 
tend to decline with age28,29. Persistence of subthreshold symptoms can still cause 
significant impairment6,30. ADHD is now accepted as representing an extreme tail of a 
continuous distribution of ADHD symptoms in the population31,32, and a diagnosis of 
ADHD is defined by high levels of core symptoms interfering with and reducing 
quality of life, academic, or occupational functioning3,4,33. It has also been shown 
that fewer ADHD symptoms are associated with a lower degree of impairment and less 
problems for the individual34. Some theoretical developmental trajectories of ADHD 
across the lifespan have been suggested, describing different levels of ADHD 
symptoms reaching the diagnostic threshold at different ages, depending on the 
increasing demands towards adulthood or accidents like brain injury (“acquired” 










Figure 1. Theoretical developmental trajectories of ADHD across the lifespan. Reprinted from Eur 
Neuropsychopharmacol, Vol 28/10, Franke et al. Live fast, die young? A review on the developmental 
trajectories of ADHD across the lifespan. 2018; 28(10):1059-1088. Copyright with permission from 
Elsevier6. 
The developmental ADHD trajectories across the lifespan is supported by a recent 
population-based study showing that persistence of ADHD symptoms in childhood and 
adolescence in the general population is associated with higher polygenic risk scores 
for ADHD35. 
The ADHD diagnosis is still made based on clinical evaluation, and no tests are 
available for diagnosing ADHD in a more objective way. Several treatment approaches 
are available; non-pharmacological (educational, dietary or behavioural interventions), 
and pharmacological options (stimulants and non-stimulants), with pharmacological 
options as the first-line treatment for individuals with moderate to severe ADHD33,36-
38.  
1.1 Diagnostic classification of attention-deficit/hyperactivity disorder 
For ADHD, two diagnostic classifications systems are currently used, the International 
Classification of Diseases, version 10 (1998) by the World Health Organization (ICD-
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10)4,39,40 and Diagnostic and Statistical Manual of Mental disorders, 5th revision (DSM-
5), by American Psychiatric Association from 20133. ICD-10 is the formal diagnostic 
system used in European countries (including Norway), using the term Hyperkinetic 
disorders, while DSM-5 was developed in the USA, with the term Attention-
deficit/hyperactivity disorder (ADHD). The DSM-system is widely used in research 
also outside the US, and the term ADHD has also gradually replaced the term 
hyperkinetic disorder in every-day language and is thus used in this thesis.  
Table 1. Simplified overview of DSM-5 and ICD-10 criteria for the diagnosis of attention-
deficit/hyperactivity disorder (ADHD) and hyperkinetic disorder (HKD), respectively. 
The symptom description is similar in both systems but differ in their categorization 
and cut-off for diagnostic thresholds. ICD-10 is more restrictive for the ADHD 
diagnosis to be fulfilled, demanding both criteria for inattentiveness (6 of 9 symptoms), 
and impulsivity (1 of 4 symptoms) and hyperactivity (3 of 5 symptoms)4, while DSM-
5 allows three ADHD clinical presentations: mainly inattentive type (6 of 9 symptoms), 
or mainly hyperactivity type (6 of 9 symptoms) or the combined type; with both 
DSM-5 (American Psychiatry Association, 2013) Symptoms 
A. Persistence 6 months and interferes with 
function/development and negatively impacts directly on 
social and academic/occupational activities 
1. Inattention >=6 of 9 (5 
of 9 for adults) 
AND/OR 
2. Hyperactivity>=6 of 9 
(5 of 9 for adults) 
B. Several symptoms present prior to age 12 years  
C. Several symptoms present in two or more settings  
D. Clear evidence of symptoms interferes with/reduce quality 
of social, academic/occupational functioning 
 
E. Symptoms occur not exclusively during 
psychosis/schizophrenia and not better explained by 
emotional, dissociative, personality disorders or substance 
intoxication/withdrawal 
 
ICD-10 (World Health Organization, 1998)  
A. Persistence 6 months 1. Inattention >=6 of 9 
AND 
2. Hyperactivity>=3 of 5 
AND 
3. Impulsivity>=1 of 4 
B. Abnormal symptoms onset before the age of 7  
C. Abnormal symptoms in at least two settings  
D. Excessive abonormality of symptoms for the childs age/ 
developmental level 
 
E. Does not meet criteria for autism, mania, depressive or 
anxiety 
 
F. IQ>50  
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inattentiveness and hyperactivity symptoms3 (see Table 1). The hyperkinetic disorder 
in ICD-10 thus corresponds to the combined phenotype in DSM-5 (which also is the 
most common of the three6,22).  In DSM-5, compared to DSM-IV and ICD-10, there is 
an adjustment for adult ADHD (individuals aged 17 or older), allowing the diagnosis 
to be given if only 5 of 6 criteria are met in each sub-phenotype of ADHD. The age of 
onset criteria also differs, in which symptoms must appear before the age of 7 years in 
ICD-10 and DSM-IV, and before 12 years of age in DSM-53,4,41. The requirement of 
symptom persistence and functional impairment is similar in both ICD-10 and DSM-
5, i.e. the symptoms should be present/impairing in two or more settings in social, 
academic or occupational situations3,4. 
In current clinical practice in Norway, the criteria of ADHD and the different clinical 
presentations from DSM-5 are widely used, although the formal diagnostic coding is 
according to the ICD-10, meaning that the code F90.0 in patient registries may include 
any of the ADHD clinical presentations described in DSM-5. Further, ICD-10 code 
F90.1 is used for ADHD with additional conduct disorder, and more rarely F90.8 and 
F90.9 for unspecified hyperkinetic deficits33,42. The dimensional perspective in ADHD 
is not taken into account by these categorical diagnostic criteria. However, this is the 
purpose of a third classification system, the Research Domain Criteria (RDoC), 
developed by National Institute of Mental Health (NIMH). RDoC was mainly 
developed for research perspective, based on dimensions of observable behaviour and 
neurobiological measures across single disorders43,44. However, even if several studies 
using the RDoC template are underway, few of them have been succesful in describing 
clinical presentations useful for prediction of outcome across traditional boundaries 
between single disorders45. 
1.2 Sex differences of ADHD across a lifespan 
“Sex is a fundamental biological characteristic that influences nearly all human traits” 
46. Thus, sex is among the most important characteristics both in somatic and mental 
health, however, the role of sex is still not fully understood. Knowledge about the 
effects of sex on risk, prevalence, prognosis, and treatment of diseases is important to 
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increase the possibility of giving the best treatment in both males and females for health 
conditions with sex differences47.  
In paper I, the term “gender” is used instead of “sex” because the study concerns adults, 
and “gender” is shaped by environment and life-experience in addition to the biological 
characteristics determined by sex48. Further, in papers II & III, focusing more on 
genetic/biological mechanisms, we use the term “sex”. In the thesis the term “sex” is 
used. 
ADHD was primarily described in young boys49,50, and later, similar diagnostic 
symptoms were recognized in girls51. The diagnostic criteria are mainly based on 
observations of school-boys, and it has been suggested that the criteria do not fit very 
well for females with ADHD51,52. However, ADHD is believed to be the same disorder 
from childhood to adulthood and for males and females, despite phenotypic differences 
expressed by sex23,53,54. 
In ADHD, there is a strong male predominance among children, with a male-female 
ratio of 9:1 decreasing to almost 1:1 in adulthood in clinical samples23,55,56. However, 
the male-female ratio is reported to be more stable between childhood and adulthood 
in community samples55,57. In the UK, two population-based studies found prevalences 
of around 3 % in boys and 0.3 % in girls32,58. The larger prevalence of ADHD for boys 
in clinical childhood samples, is suggested to be due to the more externalized behaviour 
in boys than girls51,59, leading to easier identification and referral6,51. In population-
based studies of adults with ADHD, the prevalence of ADHD in men ranged between 
2.1-5.4%, and in women between 1.1-3.2%55,57. Thus, the difference in male-female 
ratio in childhood and adulthood may be influenced by the difference in referral source, 
from teacher/parent referral in childhood to self-referral in adulthood51,52. 
The inattentive subtype is more frequently diagnosed in women with ADHD3,23. This 
may reflect a relative absence of hyperactive/impulsive symptoms more than excessive 
inattentive symptoms in women compared to men52. In line with this, both the 
hyperactivity and the combined subtypes are less likely to be diagnosed in women60.  
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Women with ADHD reported a greater subjectively experienced impact of negative 
life events compared to men with ADHD61, while another study assessing objective life 
events, like repeated grades, showed no sex differences62. Further, in a study based on 
self-reports among adults, women with ADHD reported a history of treatment for other 
psychiatric disorders more often than men13. Women with ADHD also reported more 
impairment compared to males23,63-65, and more comorbid internalizing symptom 
disorder like anxiety and depression51,52,66. Men  were more frequently diagnosed with 
the combined subtype with more externalizing symptoms29, and SUD and anti-social 
personality disorder were more often diagnosed23,52. The observation that females 
appeared to be more severely affected and impaired by ADHD compared with males 
despite a lower prevalence, is called the “gender paradox”52. Twin- and adoption 
studies of children with ADHD have estimated the heritability of ADHD to be 76%67. 
Later studies in adults found a heritability of ~35% in studies when using self-reported 
ADHD symptoms68,69. When using cross-informant data, with either combined parent 
reports and self-ratings or clinical diagnoses information, the heritability estimate was 
found to be the same in adults as for children, ~80%70. The genetic heritability may be 
different in males and females, as a putative “female protective effect” in ADHD is 
discussed71,72. In epidemiological studies, the “female protective effect” implies that 
females require greater exposure to genetic and environmental factors associated with 
ADHD in order to develop the condition54,72,73. A higher genetic load in females is 
suggested to explain the increased risk of ADHD (and other psychiatric disorders) in 
siblings of female probands with ADHD compared to siblings of male probands72,74. 
Interestingly, this “protective effect” occurs in either sex with the lower prevalence, 
and was originally developed by Cedric Carter in the 1960s, therefore, also called the 
“Carter-effect” or the sex- dependent liability threshold46. However, in a recent study 
of molecular genetic analyses, the autosomal common genetic variants could not 
explain the sex bias in ADHD prevalence74.  
Nevertheless, sex-specific heritability has been estimated in 551 traits from the UK 
Biobank, and significantly different heritability in males and females were found for 
only 2.5% of these traits75. This means that heritability estimates for males and females 
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are similar for most traits. Further, in all phenotypes with sex differences in the 









Figure 2. Clinical presentation of sex/gender-differences in ADHD, underlying mechanisms and future 
outlook. Oxford Textbook of Attention Deficit Hyperactivity Disorder, edited by T Banaschewski. D 
Coghill, A Zuddas © Reproduced with the permission of the Licensor through PLSclear76. 
In spite of the differences between men and women with ADHD regarding prevalence, 
symptom presentation, psychiatric comorbidity and heritability (see Figure 2), only a 
minority of studies of ADHD have acknowledged the possibility of an effect of sex52. 
Therefore, these questions remain to be fully explored in large representative 
population-based samples. Few previous studies have evaluated sex differences in 
comorbidity among adults with ADHD, and the results are conflicting. Most of the 
previous studies have been small and under-powered23; the male-female ratio has been 
high23,77,78; most study populations have been young78,79; self-report or screening 
questionnaires were used more than clinical diagnoses80, or without appropriate 
comparison group52. Some studies did not find any sex difference62,80. Few studies were 
population-based and large enough to study smaller groups of different psychiatric 
disorders52. A better understanding of sex differences is critical for developing 
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informed diagnostic assessment and tailored treatment strategies for both men and 
women with ADHD and gaining more knowledge about development of ADHD.  
1.3 Psychiatric comorbidities in ADHD 
Comorbidity refers to any additional co-existing disorder in a patient with a defined 
index disease81. In the study of psychiatric comorbidity in this thesis, I have chosen to 
differ between neurodevelopmental disorders and other psychiatric “symptom 
disorders”. Neurodevelopmental disorders are a group of conditions described by 
childhood-onset and impairment or developmental delay2. The neurodevelopmental 
disorders are assumed to be childhood-onset even if individuals are first diagnosed as 
adults6. Neurodevelopmental disorders comprise, e.g. learning disorders, speaking 
difficulties, intellectual disabilities, autism spectrum disorder (ASD), and ADHD, and 
do not have overlapping diagnostic criteria2. Psychiatric “symptom disorders” typically 
have a later onset in childhood, adolescence and adulthood82, like the six studied 
disorders in papers I & II, e.g. anxiety, major depressive disorder (depression), bipolar 
disorder (BD), personality disorders (PD), schizophrenia spectrum disorder 
(schizophrenia), and substance use disorder (SUD). In these disorders, the diagnostic 
criteria are sometimes overlapping, both with each other and also with some symptoms 
of the neurodevelopmental disorders, like inattention. Inattention is a criterion both for 
depression and ADHD. Both neurodevelopmental disorders and psychiatric “symptom 
disorders” can co-occur with each other and are then defined as psychiatric 
comorbidities. Recent genome-wide association (GWA) studies have shown that 
genetics are shared to some extent between both neurodevelopmental and psychiatric 
“symptom disorders”83. To sum up, the extensive comorbidity among 
neurodevelopmental and other psychiatric disorders seem to be caused both by 
overlapping diagnostic criteria, shared genetic factors, and probably to some degree 
other similar causal factors2. 
The index disorders discussed in this thesis are the neurodevelopmental disorders 
ADHD (papers I-III) and ASD (paper II), in which whenever diagnosed, are 
considered to have an onset in childhood. Therefore, we assume that ADHD or ASD 
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was present before the psychiatric comorbid disorders, which all are typically 
diagnosed in late adolescence and adulthood82. Comorbid disorders in an individual 
can alter the clinical course by affecting the time of detection, prognostic issues, the 
choice of therapy, and the therapeutic outcome of the index disorder81. Therefore, it is 
important to gain knowledge on the comorbidity pattern of individuals with ADHD 
both to tailor the best treatment for the individual patient and to inform further research 
of biological/etiological mechanisms.  
Adults with ADHD have a life-time risk of comorbid psychiatric disorders of ~80% 
17,84,85. Several studies have focused on psychiatric comorbid disorder in adults with 
ADHD, e.g. anxiety and depression23,57,85, BD 17,23,85-87, PD 88,89, schizophrenia 78,87,90, 
and SUD23,80,85. Recently, a large GWA study demonstrated that common genetic 
factors are shared between several different psychiatric disorders, including ADHD83. 
However, the risk for other psychiatric comorbidities in individuals with ADHD may 
also be mediated through other behavioural symptoms developing as a consequence of 
ADHD, e.g. SUD may be mediated by conduct disorder in childhood, and antisocial 
behaviour in adulthood91-94. 
Increased knowledge about psychiatric comorbidity in adults with ADHD, including 
sex differences, is of importance for clinicians trying to find the best treatment for the 
individual patient. In addition, information about sex-specific patterns of psychiatric 
comorbidities can inform further research investigating biological mechanisms in 
ADHD. In papers I-II, we focus on the six above-mentioned psychiatric disorders, 
typically diagnosed in the adolescence/young adulthood82, and in paper II, we compare 
the risk of these six psychiatric disorders among adults with the neurodevelopmental 
disorders ADHD and ASD.  
1.4 Psychiatric comorbidity in adults with autism spectrum disorder  
Autism spectrum disorder (ASD in this thesis) is an umbrella term of highly heritable 
pervasive neurodevelopmental disorders with childhood-onset3,95,96. ASD has a 
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considerable impact on the individual, family, social life, and educational and 
occupational attainment95.  
In DSM-IV, ASD was defined by a triad of characteristics: impairments both in social 
interaction, communication, and restrictive, repetitive, and stereotyped behaviour, 
interests, and activities41. DSM-IV further described four separate categories of autistic 
disorder: Asperger syndrome, childhood disintegrative disorder, and pervasive 
developmental disorder-not otherwise specified. In DSM-5, these subcategories are 
now put into one umbrella term “autism spectrum disorder”3. The new criteria better 
emphasize the dimensional nature of autism.  
ICD-10 precludes a diagnosis of ADHD if the criteria of ASD is met4. However, since 
the publication of ICD-10, extensive research has shown that ADHD and ASD often 
co-occur97-100. Further, genetic, epidemiological and twin studies97,99-103 have 
demonstrated common underlying genetic factors between the two disorders, with an 
estimated genetic correlation of 0.36104. The structure and function of molecular 
networks in the brain are possibly influenced by the shared genetic factors in the 
etiology of ADHD and ASD37,104. The DSM-5 thus now allows the combination of 
ADHD and ASD to be diagnosed as comorbid disorders, and this has also been 
implemented into clinical Norwegian guidelines42. However, even if significant genetic 
correlations between different phenotype-specific traits of ADHD and ASD have been 
demonstrated98,104-106, the core phenotypic characteristics of these two 
neurodevelopmental disorders remain quite different3,4,98.  
In addition, studies have reported more impairment in children with both ADHD and   
ASD than in children with only one of the disorders102,107. 
Reported prevalences of ASD have increased from 4.5 in 10,000 individuals to 62-70 
in 10,000 worldwide108,109. However, estimates of 1-2% have been shown in recent 
surveys95,110. This increase is explained by improved awareness and recognition, as 
well as changes in diagnostic criteria95,108. There is a considerable sex difference in the 
prevalence of ASD, with early studies showing a male-female ratio of 4:1, while later 
large population-based studies have shown that 2-3 times more males are affected. 
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Under-recognition of females with ASD might be an explanation111,112. Like in ADHD 
it seems like affected females “need” more cognitive or behavioural impairments than 
males to be diagnosed. This may be explained by females having better compensation 
abilities or by the “female protective effect” previously described for ADHD, where 
females are suggested to need a higher genetic load to develop the symptoms needed 
to fulfill the criteria for the diagnosis110,111.  
As in individuals with ADHD, adults with ASD also have a high risk (~65-90%) of 
developing comorbid psychiatric disorders113,114, but with seemingly different patterns 
of comorbidity. Anxiety and depression frequently co-occur in adults with ASD114, and 
the same is true for BD and schizophrenia115-117. Studies of sex differences in 
psychiatric comorbidities in adults with ASD are almost absent, mainly because of the 
late acknowledgment and practice of diagnosing ASD in adults102,107. As demonstrated 
in studies of individuals with ADHD, ASD also share genetic factors with the above-
mentioned psychiatric disorders83. Both overlapping diagnostic criteria, shared 
symptoms and pathophysiology or secondary effects of living with ASD, could explain 
the high prevalence of comorbidities95. A recent study from Bai and colleagues, shows 
that the risk of ASD is primarily genetic with little or no effect of shared 
environment118. The genetic factors are complex and polygenic, including both rare 
genetic variants with large effect sizes and common variants with smaller effect 
sizes104,119,120.  
Patterns of psychiatric comorbidities have not been systematically studied and 
compared between adults with ADHD or ASD, except for a couple of small clinical 
studies121,122, and no large study has taken sex differences into account. Further, 
comparable studies in adults with both ADHD and ASD are lacking102,107. To our 
knowledge, only a single population-based study on psychiatric comorbidity has 
compared individuals with ADHD alone, ASD alone or both ADHD and ASD, with 
individuals without ADHD and ASD. This study was, however, carried out in a 
population too young to be diagnosed with the psychiatric disorders of interest, which 
are all usually diagnosed in early adulthood123. Further, the contradictory findings of 
both shared genetics and different phenotypic characteristics in ADHD and ASD 
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remain unanswered. No previous study has compared the epidemiological patterns of 
psychiatric comorbidity with patterns of genetic correlation between the corresponding 
traits in individuals with ADHD or ASD. Such comparison could be informative 
regarding possible underlying factors.  
1.5 Risk factors for ADHD 
ADHD is an etiologically multifactorial disorder involving genetic, environmental, and 
gene-environment interaction risk factors5, with strong evidence of familial origin 
based on family, twin and adoption studies and large-scale genome-wide association 
studies5,36,70, see Figure 3. 
Figure 3. Developmental course of adult ADHD. Describes possible risk factors that influence the development. 
Reprinted by permission from Macmillian Publishers Ltd: Nature Reviews Disease Primers © 201537. 
Genetic factors 
Heritability is defined as the proportion of the variance of a phenotype that is explained 
by genetic factors124. In adults with ADHD, the heritability is ~80%, mainly shown in 
genetic epidemiology using cross-informant approaches via either parent and self-
ratings or clinical diagnoses70. 
Genetic factors thus play a vital role in the etiology of ADHD5, and ADHD also shares 
genetic factors with other psychiatric disorders83,125. ADHD is now recognized as a 
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polygenic disorder, which means that many common genetic variants contribute to the 
risk, each having very small effects. Common genetic variants are usually defined as 
having a frequency greater than 1% in the population and rare genetic variants smaller 
than 1%5. However, it has been difficult to establish the exact genetic mechanisms 
explaining ADHD. Research on single candidate genes of ADHD important in 
pathways of drugs that successfully treat ADHD has shown contradictory results and 
has not succeeded in explaining the etiology of ADHD5,24,126. Some rare genetic 
variants have also been found to play a role in rare syndromes often diagnosed with 
ADHD, like di George syndrome/velocardiofacial syndrome5.  
 
Different genetic variants contribute to the risk of ADHD through rare and common 
variants, by gene×environment interaction as well as by parent-of-origin effects (POE), 
as demonstrated by GWA studies5,127. POE refer to the different contribution from 
mothers and fathers’ genotype to the development of a phenotype in their offspring, 
and this can influence the heritability/recurrence of ADHD128. Genomic imprinting, 
effects of the maternal genome on the intrauterine environment (i.e pre- and perinatal 
factors like premature birth129, intra-uterine growth restriction130), mitochondrial 
genome and sex chromosomes, are examples of genetic mechanisms that could account 
for such differential parental effects46,127. Genomic imprinting results in the expression 
of only one of the parents’ chromosomes131. Methylation of the DNA is one of the 
mechanisms that can lead to alterations of gene expression, defined as epigenetics. 
Some of the studied examples of genomic imprinting, indicate a paternal effect in 
schizophrenia132,133, and maternal134 or paternal transmission in BD135. However, in the 
field of ADHD research, studies on DNA methylation are still scarce127,136. 
 
The primary task of the sex chromosomes is to determine the sexual differentiation of 
ovaries in females and testes in males and production of sex steroid hormones46. Males 
are more vulnerable to some recessive disorders because they only have one X-
chromosome (e.g. Duchenne syndrome, Rett syndrome, fragile x syndrome), thus if a 
recessive X-linked gene causes disease, this will be expressed. Females with a mutation 
on one of the X-chromosomes are more protected if there is a functional allele on the 
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other X-chromosome. However, more subtle gene expression in the X-chromosome in 
females may contribute to polygenic complex disease (like ADHD), but the 
contribution of sex chromosomes to non-syndromic traits is less characterized46. 
“Genetic nurturing effect” is the term of an alternative causal pathway for maternal and 
paternal effects on the child after birth, i.e. an environmental effect with a genetic 
component137. An example of “genetic nurturing effect” is educational attainment 
where the attained educational level of parents influences the environmental effect for 
the child, but with a genetic component137. The effect size can differ between fathers 
and mothers even if both parents contribute to genetic nurture137. Kong and colleagues 
found that both parents have similar effects on educational attainment, and mothers had 
a stronger nurturing effect on health aspects of the child than fathers137. The genetic 
nurture effects are likely to be bi-directional between the parent and the child, however, 
might dominate from the parents to the child137. 
Previous studies have shown conflicting results regarding maternal and paternal effects 
in ADHD. Several genetic studies found that transmitted ADHD risk alleles from 
mothers and fathers were equally related to ADHD in the offspring138-141. Two studies 
found a larger effect from maternal ADHD on risk in offspring142,143. Regarding the 
parental effect by offspring sex, one study found that ADHD risk allele transmission 
from either parent was strongest to daughters144. However, most of these studies were 
small and originate from a time when being diagnosed with ADHD as adults were less 
likely. Further, no population-based epidemiological study has yet been large enough 
to examine parent-offspring recurrence of ADHD by both parental and offspring sex. 
The evaluation of POE on ADHD recurrence risk in epidemiological data can add new 
information about the heritability and transmission of this trait. This will also increase 
knowledge that may prove to be important for earlier diagnosis and treatment for 
offspring of parents with ADHD. 
Environmental factors 
A heritability of ~80% in ADHD means that ~20% of the etiology is explained by 
environmental factors. Several environmental risk factors have been associated with 
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ADHD, from maternal smoking during pregnancy145 to postnatal factors like negative 
life events61,146, parenting style147, and parental mental health148. However, most of the 
environmental risk factors for mental disorders are non-specific in that they are 
associated with a range of different disorders149,150, e.g. reduced fetal growth and 
neurodevelopmental disorders130.   
Socioeconomic factors (SES) or social determinants are documented to affect a variety 
of disorders and aspects of health and are important to assess151, and may also 
contribute to the high prevalence of psychiatric comorbid disorders in individuals with 
ADHD. Individuals with ADHD have lower education and occupational disability 
compared to individuals without this condition12,13. Further, the causality for some of 
these risk factors has been difficult to prove, as unmeasured familial confounding may 
explain the associations 152. Such unmeasured familial confounding may, however, be 
assessed by study designs examining whether the associations with (shared or non-
shared) environmental factors persist within sibling pairs or twin pairs, since they will 
be partly matched with the cases regarding for example, socioeconomic status and 
genetics69. A couple of recent studies controlling for this confounding have confirmed 
that fetal growth was associated with several mental health conditions like ADHD130, 
and that maternal infection during pregnancy did not show an association with ADHD 
when controlling for unmeasured familial confounding153.  
Reproduction patterns in men and women with psychiatric disorders 
Parent-offspring and transgenerational recurrence risk of psychiatric disorders may 
also be influenced by specific reproduction patterns for individuals with the actual 
disorder.  Reproduction is here evaluated at the age of 45 when close to 100% of 
mothers and 98% of fathers had finished their reproduction in the Norwegian 
population. A recent report on reproduction in Norway showed that 10% of women and 
25% of men have not had any child by the age of 45 years154. In individuals with 
psychiatric disorders, the reproduction is generally lower compared to their unaffected 
siblings, especially in men155. Further, lower reproduction rates in both men and 
women with versus without ADHD were found in a Danish study focusing on teenage 
parenthood156. They also reported that among those who had children, the proportion 
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starting their reproduction at a young age was higher among individuals with ADHD156. 
Large-scale epidemiological studies with the possibility of including such information 
show that women with ADHD become mothers at a younger age compared with 
women without ADHD157. This is further confirmed in a study by Demontis and 
colleagues where they evaluated the genetic correlation between ADHD and various 
reproductive factors. They found a negative correlation with age of first birth (rg= -
0.61) and a positive correlation with the number of children ever born (rg=0.42)158. 
There is also an increased risk of ADHD in offspring of young parents159,160. 
Reproduction patterns are therefore important to consider when studying 
transgenerational recurrence risks, especially when evaluating sex-specific recurrence 
risks. 
Literature review completed September 2019. 
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2. Aims of the thesis 
The overall objective of this thesis was to gain more knowledge about psychiatric 
comorbidity and heritability patterns in adults with ADHD using nation-wide 
population-based registries that are large enough to study subgroups of ADHD. The 
work has a particular focus on sex differences in psychiatric comorbidity and 
transgenerational recurrence risks. 
Specific research aims were:  
I. To investigate sex differences in psychiatric comorbidities in adults with 
ADHD (paper I). 
II. To investigate patterns in psychiatric comorbidities in adults with ADHD 
only, ASD only or both compared to unaffected adults, and evaluate these 
patterns with genetic correlations from summary statistics (paper II). 
III. To examine the recurrence risk of ADHD across generations by parent and 
offspring sex, while taking account of reproduction patterns in men and 







3. Material and Methods 
Table 2. An overview of material and methods used in papers I-III. 
 Paper I Paper II Paper III 
Aims To investigate the 
risk of psychiatric 
comorbidity in 
adults with ADHD 
by sex 
To investigate the risk of 
psychiatric comorbidity in 
adults with ADHD only, ASD 
only, or both ADHD and 
ASD, and evaluate the risk 
patterns in light of genetic 
correlation 
To investigate the recurrence of 
ADHD from parents to child, by 
parent and offspring sex 
Data source Papers I-III: Medical Birth Registry of Norway (MBRN), Norwegian Prescription 
Database, Norwegian Patient Registry, National Education Database 
Paper II: In addition, summary statistics from relevant large GWAS 






Population Adults born 1967-1997 
n=1.7 million 
All born 1967-2011 
n= 2.5 mill 
Reproduction cohort born 1967-
1968 
Exposure Adults with ADHD 
(n= 40,103) 
Adults with 
ADHD/no ASD  (n=38,636) 
ASD/no ADHD   (n=7,528) 
ADHD+ASD       (n=1,467) 
I. Mothers and fathers with 
ADHD and offspring in MBRN  
M+/F-  (n=20,032) 
M-/F+  (n=16,952) 
M+/F+ (n=1,545) 
II. Mothers and fathers with 
ADHD registered as born in 
MBRN, linked to own children in 
MBRN 
Outcome Adults diagnosed with anxiety, depression, bipolar 
disorder, personality disorder, schizophrenia and 
substance use disorder 
Male and female offspring with 
ADHD identified in MBRN 
Covariates Year of birth, maternal marital status, maternal and 
paternal age at delivery, parental attained education, 
gestational age, gestational age- and sex specific 
birthweight z-scores, parental psychiatric diagnoses  
Year of birth 
Statistical 
methods 
Poisson regression  Poisson regression 



















3.1 Data sources 
The national central health registries are used for health analysis, health statistics, 
improving the quality of healthcare, research, administration, and emergency 
preparedness to maintain national functions of health services. Clinicians are obliged 
by law to send data to the registries electronically. All registries are regulated by The 
Personal Health Data Filing System Act which is further specified in registry-specific 
regulations and provide the legal basis for these registries161,162. Information about the 
registries is similar to the information in Supplementary of papers I- III. 
Figure 4. Overview of periods covered by the different registries for this PhD-project. 
The Medical Birth Registry of Norway 
The Medical Birth Registry of Norway (MBRN) is a nation-wide, population-based 
medical health database. The MBRN, the oldest national birth registry in the world163 
was established in 1967 after the Thalidomide disaster and contains information about 
all births in Norway, including spontaneous abortions and stillbirths from 16 weeks of 
gestation164. The aim of the registry is to clarify the causes and consequences of health 
problems related to pregnancy and birth and monitor the incidence of adverse 
outcomes. The registry is based on compulsory notification and includes demographic 
information on both the mother and father, data on maternal health before and during 
pregnancy, e.g. chronic diseases like diabetes and hypertension, pregnancy 
complications, complications and interventions during delivery, and birth outcomes.  
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Information on the infant, such as vital status, anthropometric measurements, and 
neonatal diagnoses including congenital anomalies, are also notified. The unique 
national identification numbers, given to all live born infants and all parents residing 
in the country, are included in the registry, and makes linkage with other databases 
possible. The MBRN is routinely linked with the National Registry to ensure complete 
notification and this linkage provides dates of death and emigration. 
The Norwegian Prescription Database 
The Norwegian Prescription Database (NorPD) is also a nation-wide health-registry 
and contains data about all drugs prescribed and dispensed in Norway since 2004165. 
The aim of the NorPD is to collect and process data on drug consumption, based on 
electronically notified data every month from all pharmacies in Norway. It is therefore 
the most complete data source with regards to information about dispensed 
prescriptions at the individual level in the Norwegian population. Drugs purchased 
without a prescription are not included, and medication given to an individual during a 
hospital stay is also not available at the individual level. For reimbursed medications, 
information about the indication is included; however, for psychiatric disorders, this 
information is only specific from 2008. The medications are classified by the 
Anatomical Therapeutic Chemical (ATC) classification system. The register provides 
the basis for research, health analyzes and overall supervision and management of drug 
use and treatment in Norway. 
The Norwegian Patient Registry 
The Norwegian Patient Registry (NPR) is an administrative nation-wide health-registry 
containing information about diagnoses and procedures given to individuals treated in 
secondary health care, both in hospitals and out-patient clinics. The main aim of the 
registry was primarily to be a basis for financial allocations/prioritizing within 
secondary health care. Diagnoses are registered by the International Classification of 
Diseases (ICD) codes (at present version 10), and interventions by the NOMESCO 
Classifications of Surgical, Medical and Radiological Procedures (NCSP, NCMP, 
NCRP) codes. The NPR was established in 1997 but has only had data available for 
linkage on an individual level from 2008.    
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The National Education Database  
The National Education Database (NED), established in 1970, contains information 
about the level of education of every Norwegian inhabitant who has received education 
in Norway from the age of 16 years. It includes data from completed lower secondary 
education to tertiary education including PhD level, and is updated every year166. 
Genome-wide association studies  
The aim of GWAS is to investigate the entire genome to detect DNA variants 
associated with a trait of interest. GWAS are well suited to study psychiatric disorders 
with complex and polygenic traits, and results have been reported for several common 
diseases, for quantitative traits that are risk factors for disorders (e.g. educational 
attainment and body mass index), and also for behavioural and social traits like social 
well-being175. GWAS identify single nucleotide polymorphism (SNPs, common/rare 
variants defined by a frequency of >/< 1% in the general population, respectively) that 
are associated with a disease or phenotype by comparing the DNA of participants 
having varying phenotypes for a particular trait or disease. Each common DNA variant 
has very small effects.  Due to the large number of multiple comparisons performed 
when studying the whole genome at a time, the observed association must have p-
values less than 10-8 to achieve statistical significance. Large samples are thus needed 
to uncover the genetic variance in the population175. Therefore, only lately a consortium 
of ADHD succeded in finding twelve loci achieving genome-wide significance in a 
meta-analysis of several previous GWAS158.  
Table 3. Overview of the genome-wide association studies used for genetic correlation analyses in 
paper II. Abbreviations: * proxy for substance use disorder (SUD); **proxy for anti-social personality disorder; ***NEO-5-personality 
traits; Neuroticism, Extraversion, Openness to experience, Agreeableness and Conscientiousness 
Trait Sample size  
(cases and controls) 
Reference 
(PubMed ID) 
ADHD 20,183 35,191 Demontis, 2019158 
ASD 18,381 27,969 Grove, 2019104 
Schizophrenia Spectrum Disorder 36,989 113,075 Schizophrenia Working Group of the 
Psychiatric Genomics C, 2014167 
Alcohol Dependence* 14,904 37,944 Walters, 2018168 
Ever_vs_never smoked* 41,969 32,066 Tobacco Genetics C, 2010169 
Bipolar Disorder 7,481 9,250 Psychiatric GCBDWG, 2011170 
Major Depressive Disorder 135,458 344,901 Wray, 2018171 
Anxiety Disorders 7,016 14,745 Otowa, 2016172 
Anti-social behaviour** Total sample=16,400 Tielbeek, 2017173 
NEO-5-personality traits*** Total sample=17,375 de Moor, 2012174 
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In paper II, we used summary statistics from large-scale GWAS for the psychiatric 
disorders examined104,158,167-174, downloaded from the Linkage Disequilibirum (LD) 
Hub GWAS share centre (http://ldsc.broadinstitute.org/gwashare/)176, see Table 2. The 
data were derived from individuals of European descent only. LD Hub is a centralized 
database of summary-level GWAS results for SNP heritability and genetic correlations 
analyses from different publicly available resources, and with a web interface for LD 
score regression analysis176. LD score regression is further described in chapter 3.4.3. 
3.2 Study-populations and design 
All three papers have a cross-sectional, population-based study design, utilizing the 
above-mentioned four nation-wide registries; the Medical Birth Registry of Norway, 
the Norwegian Prescription Database, the Norwegian Patient Registry and the National 
Educational Database of Statistics Norway. In addition, we use a generational design 
in paper III. To guide the reporting of these studies, we used the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE)177. STROBE has been 
developed to improve the quality of reporting observational studies177. In paper II, we 
also used data from large summary statistics from GWAS described in section 3.1.4. 
3.3 Exposure variables, outcomes and covariates 
Exposure variables 
The primary exposure variable in papers I-III was “having an ADHD diagnosis in 
adulthood”, and in addition, in paper II, a diagnosis of ASD in adulthood.  
In paper I, we defined the exposure variable “‘having an ADHD diagnosis in 
adulthood” as being either dispensed ADHD medication during 2004 to 2015 registered 
in the NorPD, or having an ADHD-diagnosis (ICD-10 code F90), registered in the NPR 
during 2008 to 2015, both at the age of 18 years or more. The ADHD medications were 
methylphenidate, racemic amphetamine, and dexamphetamine as well as atomoxetine. 
Individuals prescribed central stimulants exclusively for narcolepsy were excluded.   
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In paper II, the ADHD-definition in adults (ADHD) was as described above, with the 
additional criterion of not having an ASD-diagnosis registered. Adults with ASD only 
(ASD) were defined as individuals with an ASD diagnosis (ICD-10 codes: F84.0-
1+F84.5+F84.8-9)157,178 who were 18 years of age or older, were registered in the NPR 
during 2008 to 2015, and having no ADHD diagnosis registered. Adults (18 years of 
age or older) with both ADHD and ASD as defined above comprised the combined 
group (ADHD+ASD). The remaining population included all adults who neither had 
been dispensed ADHD medication registered in the NorPD nor had an ADHD or ASD 
diagnosis registered in the NPR. Since both ADHD and ASD are neurodevelopmental 
disorders, we assume that they were present before the psychiatric comorbid disorders, 
which all are typically diagnosed in late adolescence and adulthood82.  
In paper III, we used the linked data-file for our main analyses with the individual as 
the observation unit, registered born 1967 to 2011 in the MBRN, and alive at record 
linkage in 2015. We had data available on both mothers and fathers for each child, 
either through record linkage or as information in the MBRN. Further, individuals 
(both children and parents) with ADHD were defined as in paper I. We defined three 
exposure groups based on parents’ ADHD: children where only the mother, only the 
father or both parents had ADHD. All remaining children served as the reference group. 
We excluded individuals where information on fathers was missing in the MBRN 
(n=19,264, 0.8%); including 455 (2.1%) offspring with maternal ADHD and 18 809 
offspring (0.8%) without maternal ADHD. 
To evaluate reproduction patterns (paper III) in men and women with and without 
ADHD, we identified, unique men (n=63,040) and women (n=60,935) born in 1967-
1968 (from the MBRN), and linked them to any own offspring born in Norway by 
2011, when potential parents were 43-44 years old. ADHD was defined as in paper I.  
Outcomes 
An outcome variable is the dependent variable observed and measured by changing the 
exposure or independent variable. 
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In papers I & II, the outcomes were the following six major comorbid psychiatric 
disorders typically diagnosed in late adolescence and adulthood82, all registered in the 
NPR, at 18 years of age or older: anxiety disorders (ICD-10 codes F40-F42); 
depression (F32-F33); BD (F30-F31); PD (F60-F61), with a separate analysis on anti-
social personality disorder (F602) (only included in the main analyses because of a 
small number of cases); schizophrenia (F20-F29); and SUD (F10-F19). For BD in 
paper I, we also included individuals who were prescribed and dispensed either lithium 
during 2004-2015 or antiepileptic drugs with mood disorders as the indication, 
obtained from the NorPD during 2008-2015 (indications for psychotropic medications 
are only available in the NorPD since 2008). However, for BD in paper II, we included 
only those who were dispensed lithium during 2004-2015 according to NorPD. The 
reason for this difference was that antiepileptic drugs with mood disorders as the 
indication, may be used also for behaviour problems and not necessarily for BD in 
individuals with ASD.  
In paper II, when analyzing genetic correlations for traits between individuals with 
ADHD and ASD, the exact corresponding outcome variables for all the six psychiatric 
comorbidities were not readily available in the current published GWAS.  Genetic 
correlations for anxiety, depression, BD, and schizophrenia were available167,170-172, but 
not for SUD and PD. To compensate for the lack of these specific disorders, we chose 
to analyze the traits “ever versus never smoked”169 and “alcohol dependence”168 as 
proxy traits for substance use disorder, since they are documented to be highly 
associated risk of SUD. For PD, only a small GWAS on anti-social personality 
behaviour has been published173. Therefore, and in addition to anti-social behaviour, 
we combined data from GWAS on the five NEO-Personality Inventory (NEO) traits174. 
The five NEO-traits are neuroticism, extraversion, openness to experience, 
agreeableness, and conscientiousness179. Personality traits are not the same as a PD, 
however, we decided to use these traits and anti-social behavior and compare the 
genetic correlations of these traits between ADHD and ASD, as the best option we had. 
The outcome in paper III was offspring ADHD by maternal ADHD only, paternal 
ADHD only or ADHD in both parents relative unaffected parents. Results were 
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stratified by offspring sex. ADHD was defined as described in section 3.3.1, but 
without an age restriction. Additional outcomes in paper III were reproduction patterns, 
evaluated as proportion of men and women born in 1967-68, with and without ADHD 
as adults, who had reproduced by 2011, and the mean and median age at their first 
childbirth (overview of the different parent-offspring recurrence analyses in Appendix 
1).  
Covariates  
Covariates are characteristics describing the participants in a study. A covariate could 
also be called explanatory variable, independent variable, or predictor. If these 
characteristics are known and registered, they can be used to control for the influence 
of each covariate and this can increase the accuracy of the results, controlling for bias. 
The covariates included in the analyses should be based on expert knowledge of clinical 
importance about the exposures, outcomes, and potential confounders180. A confounder 
is defined as a variable associated with the exposure which is an independent risk factor 
for the outcome (a common cause), and not in the causal pathway180. 
To evaluate how risk factors for both ADHD (and ASD in paper II) and other 
psychiatric disorders influenced the relative risk we ran two regression models, 
including covariates obtained from the MBRN. We adjusted for the same covariates 
when calculating the risks on the relative scale in papers I & II. All covariates have 
been documented as risk factors for ADHD and for psychiatric disorders129,146,181-186:  
Model I: year of birth (5-year groups from 1967 to1997, with 1967-1973 as the 
reference), maternal marital status (single, married/cohabiting (reference category), 
other) , maternal age (<20, 20-24, 25-29 (reference value), 30-34, 35-39, 40+) and 
paternal age (<20, 20-24, 25-29, 30-34 (reference value), 35-39, 40-44, 45-49, 50+) at 
delivery, parent’s highest attained educational level at record linkage (low (<10 years 
of education), middle (10-12 years of education) and high level (>12 years of education 
(reference category)), the individual’s gestational age in weeks (<27, 28-31, 32 to 34, 
35 to 36, 37 to 41 (reference value), 42+) and gestational age- and sex specific 
birthweight z-scores (<-2.0; -2.0 to -0.51; -0.5 to 0.5 (reference value); 0.51 to 2.0; 
2.01+). Model II: the same covariates as in model I, and additionally mothers’ and 
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fathers’ psychiatric diagnoses (yes/no), including ADHD or any other psychiatric 
diagnosis from the NPR, from 2008 to 2015. 
In papers I and II, when calculating the prevalence differences on the absolute scale, 
we adjusted for year of birth of the included individuals. 
In paper III, as our main aim was to evaluate the risk of offspring ADHD from mothers 
and fathers with and without ADHD, no confounding variables were relevant, as 
illustrated by the directed acyclic graph (DAG) in Figure 5. Thus, we only adjusted for 









Figure 5. Proposed Directed Acyclic Graph (DAG) exploring the causal pathway in the study 
relevant for paper III. (DAGitty.net) 
3.4 Statistical analyses 
The main aim with statistical analyses is to explore the association between variables 
of interest, e.g. between ADHD and psychiatric comorbidities. When relations are 
complex and many variables must be considered, a method of choice is to model 
associations using an appropriate multivariable regression model. In a regression model 
used for evaluating mechanisms and causal factors (a causal model), we include 
explanatory variables that are potential confounders, i.e. independent risk factors for 
the outcome, associated with the exposure in the source population and not affected by 
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neither the exposure nor the outcome.  We need to use our expert knowledge to choose 
explanatory variables of clinical and biological/physiological importance180, and a 
graphical method like a DAG may be helpful when evaluating what variables to include 
in the final statistical model. An example is shown in Figure 5 for the analyses in paper 
III. Finally, it is important to evaluate whether the data fulfill the conditions of the 
statistical model.  
Two-sided tests with a significance level of p<0.05 were chosen for statistical 
significance in all analyses, and the prevalence differences (PDs), prevalence ratios 
(PRs), and relative risks (RR) were expressed with their corresponding 95% confidence 
intervals (CI). 
Analyses for all three studies were carried out with SPSS version 22.0/23.0 (IBM 
Corp., Armonk, NY) and STATA Intercooled version 14 (StataCorp, College Station, 
TX).  
Regression  
In all three papers, the associations between the exposure of interest, and the outcomes 
were estimated by using predicted prevalence from a Poisson regression model with 
robust standard errors187. Poisson regression models are generalized linear models, a 
form of regression analysis used to model count data. Robust error variance procedure 
was used to rectify the overestimation of the error for the estimated relative risk187. An 
important assumption of regression analysis is that all observations are assumed to be 
independent. To “cluster” means to take into account the fact that one individual might 
contribute to several observations or that one observation is being dependent on another 
observation. The mother’s identification number was used as a cluster variable in the 
analyses to account for correlations (or dependency) between siblings in paper I & 
II188. 
Absolute measures versus relative measures 
Absolute effect measures are differences in occurrence, while relative effect measures 
are ratios of occurrence measures189. While it has been suggested that effect measures 
and interactions on the relative scale are better suited to “assess causality”, risk 
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differences and interactions on the absolute scale are the most important to assess 
public health relevance, indicating which group may benefit the most from treatment 
or preventive measures190. Nevertheless, it is recommended to report the results on both 
the relative and the absolute scales, and if not, it is important to clarify on which scale 
the effect measures are analysed. 
On the absolute scale, we estimated prevalence differences (PDs) (papers I-II) of 
psychiatric disorders in men and women with and without ADHD, and in paper III, 
PDs of ADHD in children in the three different exposure groups of parents with and 
without ADHD. We also estimated adjusted prevalence rates in all three papers. On the 
relative scale, we estimated prevalence ratios (PRs) (papers I-II) and relative risks 
(paper III) comparing the same groups, i.e. we reported measures on both the absolute 
and relative scales in all three papers. In line with this, we evaluated effect 
modification/interaction on both the additive and multiplicative scales (see 3.4.4). 
Linkage disequilibrium score regression 
Linkage disequilibrium (LD) quantifies the similarities in genetic architecture between 
two traits by evaluating the relationship between SNP association strengths and genetic 
LD125. SNPs are the most common type of genetic variation among people. Each SNP 
represents a difference in a single DNA building block, called a nucleotide. LD is the 
non-random association of alleles at different loci in a given population. Loci are said 
to be in LD when the frequency of association of their different alleles is higher or 
lower than what would be expected if the loci were independent and associated 
randomly191.   
Linkage disequilibrium score regression (LDSC) was used to examine the association 
between LD scores and the test statistics of the SNPs from the GWAS which were 
downloaded from the Linkage Disequilibirum (LD) Hub GWAS share centre 
(http://ldsc.broadinstitute.org/gwashare/)176. Due to sample overlap between the 
examined datasets, the correlations were calculated without constraining the intercept. 
In all analyses, the examined data were restricted to SNPs of good imputation quality 
(IMPUTE Info metric ≥ 0.8 (high-quality)), and common genetic variation (≥ 1%). To 
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account for multiple testing, Bonferroni correction was applied to a significance 
threshold of 0.05, bringing the adjusted significance threshold to 0.00625.  
Genetic correlations (paper II) were calculated using LDSC from relevant GWAS. 
Genetic correlations denoted rg, is defined as the proportion of variance shared between 
two traits explained by genetic factors. A genetic correlation of 0 implies that the 
genetic effects on one trait are independent of genetic effects on the other, while a 
correlation of 1 implies that all the genetic influences on the two traits are identical. 
Different traits are analyzed in paper II, from disorders like ADHD to traits like 
“ever_vs_never_smoked” and “neuroticism”. To analyze the five GWAS on NEO-
traits for personality in paper II, the METAL software was used. METAL is a tool 
developed to do metanalysis of GWAS192.  
Interaction – on the additive and multiplicative scales 
Possible effect measure modification (interaction) by sex was evaluated in both paper 
I and paper II. An interaction occurs when the effect of one causal variable on an 
outcome depends on the state of a third variable. It is important to explore the effect of 
exposure in different levels of the third variable (stratify on the potential effect 
modifier), e.g. if the association of ADHD on the risk of SUD is the same in men and 
women. On the multiplicative scale, one method to test this potential difference in 
effect (interaction) is to do regression analyses with an interaction term. This interaction 
term is handled as a new variable, a product of the two relevant variables190. The model 
gives a p-value and a confidence interval for the interaction term and statistical 
significance can be evaluated, e.g. if the effect of exposure on outcome differs 
significantly among men and women. 
Statistical interaction is dependent on the scale used as described in section 3.4.2. In a 
recent guide on interaction analysis, it is recommended to estimate interaction both on 
the relative and absolute scales190. 
In papers I & II, significance of interaction by sex on the multiplicative scale was 
evaluated by comparing Poisson regression models with and without the interaction 
term (sex x ADHD) included, as tested by likelihood ratio tests. Further, the 
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significance of interaction by sex on the additive scale was evaluated using relative 
excess risk due to interaction (RERI)190.  
Population Attributable Fraction 
Population attributable fraction (PAF) is a way of quantifying the contribution of a risk 
factor to the burden of a disease or death in the population. PAF is a measure used to 
assess the public health impact of exposures in populations, and in a population, the 
fraction of all cases with a particular disease or adverse condition that is attributed to a 
specific exposure is defined as the PAF193. The term “attributable” has a causal 
interpretation: PAF is the estimated fraction of all cases that would not have occurred 
if there had been no exposure193,194. In paper I, we estimated the proportion of the 
studied psychiatric disorders in the adult population that could be attributed to a 
comorbid ADHD among men and women with ADHD (Attributable fractions in the 
exposed - AFE) and in the population (PAF). 
Missing information – using multiple imputation 
In research, missing data are a common problem. Missing data need to be handled in a 
correct way to avoid bias of the results. If the information is missing at random, the 
best way of handling this is to use multiple imputations, where missing data for a 
subject are imputed/replaced by a value that is predicted using the subject’s other, 
known characteristics195. 
In papers I & II we used multiple imputations with chained equations (MICE)196 in 
sensitivity analyses to evaluate possible biases due to missing information in 
gestational age when adjusting for gestational age and birthweight by gestational age 
z-scores. In the main analyses, missing values in covariates (6% for gestational age and 
birthweight z-scores, other variables < 1%) were handled by listwise deletion. We ran 
sensitivity analyses using MICE to impute the missing values in gestational age and z-
scores. Variables used in the MICE analyses were the outcome variables, all specified 
covariates and also birthweight, maternal preeclampsia and mother’s chronic diseases 
(yes/no), all known to be associated with gestational age and birthweight. 
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3.5 Ethical approval 
All three studies were approved by the Regional Research Ethical Committee of 
Norway, (2011/2272). No informed consent was required for the analyses as the 
records were anonymized.  
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4. Summary of main results 
4.1 Paper I 
Paper I is a population-based study of associations between ADHD and psychiatric 
comorbidities in adults, and how these differ by sex. By linking Norwegian national 
registries, we identified 40,103 adults with ADHD (44% women) and compared them 
with 1,661,103 adults (49% women) in the remaining population, all born from 1967 
to 1997. ADHD and BD were registered in the NorPD from 2004 to 2015, and BD and 
other psychiatric disorders in the NPR from 2008 to 2015. Prevalence differences (PDs) 
and prevalence ratios (PRs) of psychiatric disorders in adults with and without ADHD 
were determined by Poisson regression. Interaction by sex was evaluated on the 
additive (for PDs) and multiplicative (for PRs) scales. Proportions of psychiatric 
disorders attributable to ADHD were calculated.   
PDs associated with ADHD were significantly larger in women than in men for 
anxiety, depression, BD and PD, e.g. depression women: 24.4 (95% CI, 23.8-24.9) 
versus men: 13.1 (95% CI, 12.8-13.4), see Figure 6. PDs were significantly larger in 
men for schizophrenia and SUD, e.g. SUD men: 23.0 (95% CI, 22.5-23.5) versus 
women: 13.7 (95% CI, 13.3-14.0). On the relative scale, the sex relations were 
opposite: Stronger associations in men than women for anxiety, depression, and PD, 
with PRs ranging from 3.7 (95% CI, 3.6-3.8) for anxiety and depression in women to 
8.9 (95% CI, 8.5-9.3) for BD and PD in men. Between 5.6% and 16.5% of psychiatric 
disorders in the population were attributable to ADHD.  
In summary, we found that the association between ADHD and psychiatric 
comorbidities differed significantly among men and women. Clinicians treating adults 
with ADHD should be aware of these frequent and sex-specific comorbidities, such 
that early identification and treatment can be offered.   
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Figure 6. Adjusted prevalences of psychiatric disorders in men and women with and without ADHD. Prevalence 
were adjusted for year of birth, 5-year periods, from 1967 to 1997, with 1967-1073 as the reference period. 
SUD= substance use disorder. 
4.2 Paper II 
In paper II, we used data from Norwegian population-based registries to assess patterns 
of psychiatric disorders (e.g. BD, schizophrenia, SUD) in adults with ADHD only 
(n=38,636; 2.3%), ASD only (n=7,528; 0.4%) and ADHD combined with ASD 
(n=1,467; 0.1%) compared to adults in the remaining population without ADHD or 
ASD (n=1,653,575). PRs determined by Poisson regression were evaluated in light of 
genetic correlations (rg) calculated by linkage disequilibrium score regression based on 
summary data from relevant genome-wide association studies. 
For all psychiatric comorbidities, PRs differed between ADHD and ASD, see Figure 
7, left panel. PRs were largest for individuals with ADHD and ADHD+ASD for most 
of the psychiatric comorbidities. However, the PR of schizophrenia was three times 
larger in ASD than in ADHD (PRASD=13.9, 95% CI, 12.7-15.2, PRADHD=4.4; 95% CI, 
4.1-4.7, p<.001), while the PR of SUD was three times larger in ADHD than in ASD 
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(PRADHD 6.2; 95% CI, 6.1-6.4, PRASD 1.9; 95% CI, 1.7-2.2, p<.001). For the genetic 
correlation analyses, the patterns were similar, although differences between ADHD 
and ASD were significant for only two comorbidities: the proxy of SUD (alcohol 
dependence and smoking) and for the proxy of personality traits (NEO-5), see Figure 
7, right panel. 
Specific and similar patterns of psychiatric comorbidities based on both 
epidemiological data and genetic correlations, contribute to our understanding of 
ADHD and ASD as being neurodevelopmental disorders with common factors, 







Figure 7. The pattern of prevalence ratios of psychiatric comorbidity in adults with ADHD and ASD observed 
in this study (ADHD; n=38,636, ASD; n=7,528) (left panel) and genetic correlations (rg) calculated from 
genome wide association studies (right panel) 
Left panel: Prevalence ratio, model II, log-scale, 95% CI error bars. Adjusted for year of birth (5-year groups, 
from 1967 to 1997, with 1967-1973 as the reference), maternal marital status (single, married/cohabiting 
(reference), other), maternal and paternal education (low (<10 years of education), middle (10-12 years of 
education and high level (>12 years of education (reference)), maternal age (<20, 20-24, 25-29(reference), 30-
34, 35-39, 40+) and paternal age (<20, 20-24, 25-29, 30-34(reference), 35-39, 40-44, 45-49, 50+) at delivery, 
gestational age (<28, 28-31, 32 to 34, 35 to 36, 37 to 41 (reference), 42+), gestational age and sex specific birth 
weight z-scores (<-2.0; -2.0 to -0.51; -0.5 to 0.5 (reference); 0.51 to 2.0; 2.01+), maternal and paternal 
psychiatric disorders (yes/no).    
Right panel: Genetic correlations, rg, linear scale, SE error bars. 
* “ever_vs_never_smoked” and “alcohol dependence” as proxies for SUD, ** ‘NEO-5-personality traits‘ 
as proxy for personality disorder. 
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4.3 Paper III 
In paper III, we aimed at evaluating whether the transgenerational recurrence of ADHD 
differed by parental and offspring sex and whether reproduction rates and proxies for 
ADHD-severity influenced this recurrence risk. The nationwide MBRN was used to 
identify individuals born from 1967 to 2011 with their parents, and those born from 
1967 to 1968 were followed to 2011 for their own reproduction. We used Poisson 
regression to calculate the adjusted prevalence and relative risk (RR) for ADHD in 
offspring of mothers with ADHD (n=20,032; 0.8%), fathers with ADHD (n=16,952; 
0.7%) or both parents with ADHD (n=1,545; 0.06%). The remaining children (of 
parents without ADHD) served as reference (n=2,447,559; 98.5%). The reproduction 
(the cumulative proportion of individuals born from 1967 to 1968 with any offspring 
by 2011 in the MBRN) was calculated for men and women with and without ADHD.  
Parental ADHD was a strong risk factor for childhood ADHD. Maternal ADHD had a 
stronger association with offspring ADHD than paternal ADHD (RRmaternal 8.4; 95% 
CI, 8.2-8.6 versus RRpaternal=6.2; 95% CI, 6.0-6.4). We found the highest recurrence 
risk when both parents were diagnosed with ADHD (RRboth11.7; 95% CI, 11.0-12.5). 
Using absolute measures, mother-son associations were the strongest, and the risk of 
offspring ADHD when both parents had ADHD was 41.5% in sons and 25.1% in 
daughters. Using relative measures, recurrence risks from maternal and paternal 
ADHD were higher in daughters than in sons, however, even higher from mothers than 
fathers (RRmother-daughters 10.4; 95% CI, 10.0-10.8; RRmother-sons 7.4; 95% CI, 7.2-7.6; 
RRfather-daughters =6.7; 95% CI, 6.4-7.1; RRfather-sons: 5.8; 95% CI, 5.7-6.1). Men diagnosed 
with ADHD had lower cumulative reproduction compared to women with ADHD 
(75.2% versus 90.4%, respectively), and were older at childbirth, compared to women 
with ADHD, see Figure 8. However, the main results were not influenced by the 
differences in reproduction patterns, see Figure 9. 
We found that transgenerational ADHD recurrence risk is high and was higher for 
maternal than paternal ADHD regardless of offspring sex and use of relative or absolute 
effect measures. This difference in recurrence risk could be due to stronger genetic 
effects from mothers, a stronger effect of non-transmitted alleles from mothers, 
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maternal health-seeking behavior, or a combination. Our results may prove helpful for 










Figure 8. The reproduction of men and women in Norway (men and women (with and without ADHD) registered 









Figure 9. Parent-offspring recurrence of ADHD. A. Mothers and fathers to offspring registered born 1967-
2011, Medical Birth Registry of Norway (MBRN). B. Mothers (born 1970-1973) and fathers (born 1967-1970), 
offspring born 1981-2011, MBRN. C. Mothers (born 1970-1973) giving birth at 20 years or more, fathers (born 
1967-1970), offspring born 1981-2011, MBRN 
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5. Discussion 
5.1 Methodological considerations  
The overall aim of this thesis was to gain more knowledge about psychiatric 
comorbidity and heritability patterns in adults with ADHD using nation-wide 
population-based registries large enough to study subgroups of ADHD. The work has 
a particular focus on sex differences in psychiatric comorbidity and transgenerational 
recurrence risks. 
To our knowledge, all three papers were the first and largest population-based studies 
on their topics; paper I in investigating sex differences in psychiatric comorbidity in 
adults with ADHD, paper II in comparing psychiatric comorbidity in adults with 
ADHD, ASD or both ADHD and ASD, overall and by sex, and comparing the pattern 
with genetic correlations from summary statistics (GWAS), and paper III in studying 
parent-offspring recurrence risk of ADHD by parent and offspring sex using 
generational data. 
In this final part of the thesis, the findings are discussed in light of the current literature. 
First, some major methodological aspects of our studies are considered. Second, the 
major contribution of our findings to the existing literature on ADHD, psychiatric 
comorbidities, and parent-of-origin effects are discussed, emphasizing sex differences.  
5.1.1 Strengths and limitations of registry-based studies 
Our main data source for defining participants in the study was the MBRN, the oldest 
birth registry in the world with information about all births in the country from 1967163. 
The MBRN is routinely linked with the National Registry, and this linkage ensures 
complete notification of births for the entire population. The unique national 
identification number given to every resident in Norway is included in all the central 
health registries and allows information from the registries used in the present study 
(NPR, NorPD, NED) to be linked. We could define our exposures and outcomes with 
information from the NPR and NorPD. 
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Internal validity and bias of data 
Bias in observational studies is any systematic factor other than the exposure of interest 
that can influence the observed result in the outcome. In observational studies, three 
sources of bias can influence the internal validity (bias or systematic error) of the study: 
selection bias, information bias and confounding197.  
Selection bias 
Selection bias is a type of systematic error caused by factors that influence the selection 
of study participants or factors influencing study participation. Selection bias exists if 
the association between exposure and outcome differs between those who participate 
and those who do not participate in the study198.  
The main strength in papers I-III is the unique data sources we used, utilizing large, 
nation-wide population-based registries with compulsory notification allowing the 
inclusion of the total population. The potential for selection bias is therefore much less 
in the present studies than in the majority of previous studies in the field, especially 
clinical studies. Our study population was based on the MBRN, covering all births in 
the country. However, since we conditioned on everyone to be alive at record linkage, 
individuals who died or emigrated before record linkage were not included. We know 
that premature mortality is higher in individuals with ADHD18, and conditioning on 
everyone to be alive at record linkage may have caused a selection bias since we may 
have lost more exposed individals (adults with ADHD) than unexposed individuals (the 
remaining population). However, mortality is very low in the age group we studied, 
also in ADHD individuals, and the number of losses is probably too low to cause a 
noticable problem. Mortality in the ADHD group could be associated with psychiatric 
comorbid disorders, e.g. suicide or accidents. Therefore, it is possible that psychiatric 
comorbidity among the ADHD individuals who died is even higher than what we find 
in the included population. Thus, if this selection bias should have influenced the 
results, it has most likely led to an underestimation of the associations. 
Information bias 
Information bias or misclassification can induce error in the results if the participants 
in the study have measurement errors in the information about the individual 
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themselves, of the exposure, or of the outcome. In epidemiological studies, 
information bias can occur even if the sample sizes are large198.  
The NPR was our main source both for the studied outcomes (i.e. psychiatric disorders 
in papers I & II, ADHD diagnosis in the offspring in paper III), and exposures (ADHD 
diagnosis in papers I-III, and ASD in paper II). Therefore, a main concern in studying 
comorbidities in this study is the diagnostic validity of the diagnoses registered in the 
NPR. Validity of a diagnosis is the degree to which this diagnosis represents a distinct 
entity across different cultures/clinicians, and is associated with explanatory variables 
like causal factors, pathogenetic mechanisms and treatment response199. In psychiatric 
disorders, this has been difficult to establish properly.  
Diagnostic validation is done for one of the exposures in paper II (ASD)200,201, and for 
two of the outcomes in papers I & II; BD and schizophrenia202, but is lacking for the 
ADHD diagnosis. However, validation of ADHD in corresponding patient registries in 
Sweden and Denmark has been done with good results87,203. This is also expected to be 
the case in Norway, as the diagnoses are always based on a clinical evaluation by 
specialists. Therefore, the validation studies from the Scandinavian patient registries 
may be comparable to the NPR.  
The prevalence of disorders in the NPR are based on the registered diagnoses in clinical 
practice and is not necessarily reflecting the real prevalence in the population. The 
information from NPR has some important limitations. We will probably underestimate 
the real prevalence of ADHD and the other psychiatric disorders for two reasons: First, 
the individual has to visit special health care service to be registered; and second, this 
must have happened after 2008 (when the NPR was available for linkage). Therefore, 
it is not possible to estimate lifetime prevalence using data from the NPR. However, 
by using information also from the NorPD, we were able to get information also from 
individuals being dispensed medication from 2004. This was possible for ADHD and 
BD for which specific medications were available for detection. We believe that this 
strengthens our study by increasing the years available and number of cases. Further, 
the specific medications we used to define ADHD and BD are only prescribed after a 
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thorough evaluation by a specialist in psychiatry/child- and adolesecent psychiatry, and 
only if diagnostic criteria are met. The prevalence of ADHD among adults (>18 years) 
in our study population was 2.4%, which is comparable with previous studies1,11. 
Therefore, we believe that our definition of ADHD has acceptable validity for this 
diagnosis in adulthood.  
Since diagnoses registered in the NPR are from specialist health care, patients who are 
treated in primary care only, will be missed. While patients with most of the severe 
psychiatric diagnoses in our studies will be in touch with specialist care, there may be 
patients with milder forms of anxiety and depression that are lost in our study. 
As mentioned, we chose to identify ADHD cases not only from the NPR, but also by 
having been dispensed ADHD medication, registered in the NorPD. This allowed us to 
increase the sample size and representation of cases, and further to compare data to 
other Scandinavian studies using the same method87,204-206. The NorPD contains data 
about all drugs prescribed and dispensed in Norway since 2004. Therefore, we have no 
information about prescriptions before 2004, and adult individuals who got an ADHD 
diagnosis before 2004, and who were not prescribed any ADHD medication after 2004, 
or who have ”outgrown” their ADHD (ADHD in remission) are missed in our study. 
This could lead to a selection of more severe adult ADHD disorder in those adults we 
capture in our studies. Further, we also know less about the most affected individuals 
with severe problems, possibly also persons with undiagnosed ADHD, who do not seek 
help/health service, i.e. individuals struggling with substance use disorders, 
criminality, without a home, or with a criminal record, as these may seek health service 
to a lesser degree. Finally, adult ADHD is a relatively new concept, and some affected 
adult individuals may not have been diagnosed because of lower awareness of adult 
ADHD, even if the prevalence of ADHD increases in adults during our study period. 
In Norway, formal diagnoses of ASD and ADHD, and decisions about pharmacological 
treatment of ADHD are always based on a clinical evaluation by specialists. Thus, 
identification of ADHD and ASD cases was not based only on symptom scores or self-
reports. Further, adults with ADHD were diagnosed by clinicians from all over the 
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country, and as the health care service in Norway is expected to be available for 
everyone, this reduces the influence of selection bias and represents a naturalistic 
clinical setting.  
Some further limitations regarding the diagnoses should be discussed. In paper I-II, it 
may be argued that adults with ADHD or ASD could more easily get other psychiatric 
diagnoses, because they are already in touch with the health care system207. However, 
all adults with severe psychiatric disorders are likely to be in touch with secondary 
health care throughout life, independent of underlying neurodevelopmental 
disorders208. In paper III it may be argued that offspring with ADHD could more easily 
get this diagnosis if parents have the same diagnosis, or vice versa. This type of bias 
could influence on the prevalence ratios and recurrence risk estimates, because of the 
health-seeking behaviour in parents, and especially if the health-seeking behaviour is 
different between mothers and fathers (paper III). Health-seeking behaviour is 
discussed more in details in chapter 5.2.1. 
Misclassification can also be a problem in psychiatric diagnostic practice, due to 
similar symptoms for several psychiatric disorders, like inattention symptoms both in 
ADHD, depression and anxiety disorders. However, this type of misclassification is 
likely non-differential between the different psychiatric disorders, expected to be 
similar among individuals with ADHD and the remaining population. We are 
comparing adults with ADHD and an additional psychiatric disorder with the 
population without ADHD (paper I & II). In a sensitivity analysis, we repeated 
analyses including only individuals with one psychiatric (comorbid) disorder, and the 
pattern and estimates were similar.  
Relevant for paper II, up to 2013 (time of introduction of DSM-5) an ASD diagnosis 
would preclude a diagnosis of ADHD according to DSM-IV and ICD-104,41. This may 
have affected the diagnostic procedures and hindered clinicians to diagnose both 
disorders if the criteria for ASD were fulfilled. However, clinical practice has not 
adhered strictly to these criteria in the nearest years before 2013, as growing evidence 
supported the importance of diagnosing both conditions when present to provide the 
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best treatment102,107. Diagnosing psychiatric comorbidities in adults with ASD is 
difficult, as most standard diagnostic tools are not customized for these 
individuals102,209 Therefore, we cannot exclude possible misdiagnosis of schizophrenia 
and ASD. To assess a schizophrenia diagnosis in a person with established ASD is 
challenging, and vice versa. However, the developmental history in ASD vs 
schizophrenia is quite distinctly different and a minimal requirement to establish the 
ASD diagnosis. Both diagnoses have a severe impact and are thus not lightly 
administered and usually applied only after lengthy observation and detailed 
assessment. 
The possibility of misclassification/overlapping, and the validity of psychiatric 
diagnoses, may also affect the results of the genetic correlation analyses in paper II, as 
they are a mix of different samples of clinically diagnosed cases and self-report cases 
from large health surveys. However, the largest GWAS of ADHD to date, showed that 
regardless of using cohorts of individuals with clinically diagnosed ADHD, a sample 
with self-reported ADHD symptoms, or a meta-analysis of quantitative measures of 
ADHD symptoms in the population, results that supported the validity of clinical 
diagnoses of ADHD to ADHD-related behaviour in the general population158.  
Confounding 
A confounder is a variable that influences both the exposure and the outcome causing 
a false association because of the presence of shared common causes, and by that, 
introduces bias198.  Confounders may be known and measured (for example educational 
level or perinatal factors in the present studies) and can then be handled in the analysis 
phase, but for most studied relations, there will also be unknown and/or unmeasured 
confounders, resulting in residual confounding. Such residual confounding must be 
evaluated for each specific situation.  
From the MBRN we had information about the perinatal variables. Several of the 
perinatal factors are associated with both ADHD (exposure) and psychiatric 
comorbidities (outcome)129,146,181-186. The perinatal factors were prospectively 
registered (birth weight and gestational age) for the whole study population, and any 
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potential misclassification of these variables would be similar for individuals who later 
do or do not develop ADHD. Adjusting for the potential confounding perinatal factors 
in paper I & II had little impact on the estimates. 
Inequality in socioeconomic level is known to influence the risk of both somatic and 
psychiatric health. Therefore, we also adjusted for socioeconomic factors in papers 
I&II, like highest attained parental education (from NED), maternal marital status 
(MBRN), and age when becoming a parent (MBRN). These adjustments also had very 
little impact on the estimates. Selection bias of participants due to socioeconomic 
factors is minimal (or practically non-existent), since the entire population is included. 
Adjustments for SES are controversial in highly heritable disorders like ADHD, as it 
is not well known where on the causal pathway the SES are located, either as a common 
cause (confounder) or as a common effect (collider). Finally, we also adjusted for 
parental psychiatric disorders (from NPR/NorPD), including ADHD (model II, papers 
I&II). This could represent common genetic factors for ADHD and other psychiatric 
disorders in the offspring, however, this adjustment reduced the estimates only slightly. 
There is a possibility for unmeasured confounding related to familial factors, which 
could have been evaluated better in other designs, such as sibling designs130,210.  
Sample size 
Another main strength in papers I-III is the large sample size, including the entire 
population in Norway. This also ensures a “real life” sex distribution, thus a large 
proportion of women with ADHD (44%), which allowed us to compare psychiatric 
comorbidity by sex with representative numbers in both groups. Further, in paper II, 
our patient groups were large enough to study subgroups of individuals with either 
ADHD only, ASD only or both conditions (ADHD+ASD). 
In our main analyses, the confidence intervals were narrow, meaning that the 
association measures were rather precise. However, in paper II, analyzing the risk of 
psychiatric comorbid disorder in adults with both ADHD and ASD, with a smaller 
number in the exposure group, the confidence intervals were broader, indicating less 
precise measures. This was also the case in some of the sensitivity analyses with fewer 
individuals in the sub-groups. However, the point estimates were high for all analyzes, 
indicating strong associations, and associations were significant also in the 
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ADHD+ASD. In very large datasets, it is a problem that associations may be 
statistically significant between prevalent exposures and almost every outcome studied. 
Therefore, triangulation (doing different models of analyses or different study design) 
can help researchers to be more confident about identifying which risks are genuinely 
causal211. 
Study design 
We used a cross-sectional design in all three papers, since both our exposures (ADHD, 
and ASD in paper II) and our outcomes were based on data registered during 2008 to 
2015 (NPR) and during 2004 to 2015 (NorPD). The differences in time-periods covered 
by the registries (MBRN, NorPD, NPR) were a major limitation (see Figure 4), and 
made it impossible to study temporal relations between ADHD (ASD) diagnosis and 
the comorbid psychiatric disorders in papers I-II. It also precluded the examination of 
whether parents received their diagnosis before or after their child (paper III). 
However, as our exposures ADHD (papers I-III) and ASD (paper II) are defined as 
neurodevelopmental disorders with onset in childhood, we assume that they were 
present before the comorbid psychiatric disorders studied (papers I-II), or in parents 
before their child (paper III).  
For papers I and II, we designed the studies specifically to examine an adult population, 
allowing all participants to reach the typical age of diagnosis of the outcome conditions 
investigated82. In addition, in paper II we had the possibility of studying the first birth 
cohort for which ASD became prevalent enough in adulthood. In paper III, since the 
MBRN has information about the mother and father of the child since 1967, we had a 
unique possibility to study the parent-offspring recurrence risk of ADHD by parental 
and offspring sex. Further, because of the size of our population-based data set we 
could study the recurrence risk in families where only the mother, only the father or 
both parents had ADHD. Finally, since the first cohorts of the MBRN had reached the 
end of their reproductive ages (~45 years) by 2011, we could study reproduction rates 
in males and females with and without ADHD.  
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In all three papers we used logistic regression, with clustered standard error in papers 
I & II. In paper III, due to the generational design, additional analyses without 
clustering was done to allow each offspring to be its own outcome and not being 
clustered together with siblings, making an average of the ADHD risk. However, doing 
both kinds of analyses did not change the point estimates, clustered analyses only 
produced slightly wider confidence intervals.  
Genetic data 
Patients’ comorbidities are not always taken into account in genetic studies, due to 
strict exclusion criteria (DSM-IV) at least in the early GWAS (e.g. in ADHD GWAS, 
individuals were excluded if comorbid ASD)158,212. Therefore, our ability to examine 
the genetic variability that may be responsible for the different psychiatric symptoms 
and phenotypes are limited in the current GWAS. At the time of our study, large-scale 
GWASs with available summary statistics was lacking for SUD and PD, as defined in 
our data. We therefore chose to examine the ‘best proxy’ of available GWAS’ 
phenotypes for these disorders, i.e. smoking habits and alcohol dependence as proxies 
for SUD, and the five NEO-Personality Inventory traits in addition to anti-social 
behavior for PD (see chapter 3.3.2). It would have been better for the comparison 
between epidemiological associations and genetic correlations if we had had available 
GWAS with information about exactly the same phenotypes, i.e. in this case the whole 
group of SUD and PD. However, as genetic vulnerability for complex disorders (like 
psychiatric disorders) is probably more correlated to underlying traits than the defined 
disorders, it may be argued that using personality traits as proxies for disorders may be 
a good approach213. Further, individuals with known combined ADHD and ASD were 
excluded from some GWAS and thus we could not study the genetic correlation of this 
combined case group.  The estimations were highly dependent on the sample size of 
the utilized GWAS with regard to the genetic correlations. Large samples are needed 
to uncover the genetic variance in the population175. Further, the GWAS were of 
European descent only, making the generalizability of the results limited to a similar 
population. 
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5.1.2 Strengths and limitations of the psychiatric diagnoses 
Mental illnesses are complex, diverse, dynamic and heterogeneous conditions, and 
their nosology, i.e. categorizing them into discrete entities by diagnostic manuals like 
the DSM and ICD classification system, is challenging. DSM-5 and ICD-10 are useful 
tools in the communication between clinicians and play an important role in research 
and clinical management, even if they are only explanatory constructs and not 
“systematic classifications” in the sense in which that term is applied in biology ; 
distinct natural entities and mutually exclusive diagnostic categories199. 
Further, the overlapping phenotypic characteristics between the different diagnoses 
often leads to several psychiatric diagnoses for each patient, included in the concept of 
psychiatric comorbidity. The increased overall number of diagnoses in DSM, from 106 
diagnoses listed in DSM-I in 1952, to 297 diagnoses in DSM-IV, and similar numbers 
in DSM-5, (however, with a change in the criteria (or tresholds) of diagnoses), 
contribute to an increased psychiatric comorbidity, as the criteria do not sufficiently 
differentiate between disorders214. Comorbidity seems to be more prevalent in the field 
of psychiatry and mental health compared to other medical fields215. This is also 
supported by the recent GWAS study from The Brainstorm Consortium, where all 
psychiatric disorders studied had some shared genetic factors, as opposed to the studied 
neurological disorders83.  
However, although not perfect, the usefulness, and utility of clinical diagnoses to the 
clinician are invaluable, and still the best tool to provide information about prognosis, 
future function and impairment, guide treatment decisions, and guide research214,216. 
Therefore, although the study of psychiatric comorbidity is challenging for these 
reasons, such studies are needed both for clinical work and to inform future research 
into possible underlying causes and mechanisms. 
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5.2 The contribution of the findings  
5.2.1 Sex differences in risk of psychiatric comorbidities in adults 
with ADHD 
Using population-based, nationwide registries, the results from our studies establish 
sufficient evidence of significant sex-specific psychiatric comorbidities in adults with 
ADHD, and sex-specific generational recurrence risks of ADHD. Sex is severely 
understudied in psychiatric research, despite being a major predictor of individual 
differences in the prevalence of psychiatric disorders45,217. As previously described in 
chapter 1.2, only a minority of studies on adults with ADHD have acknowledged the 
possibility of an effect of sex, and the few exisiting studies have shown conflicting 
results52 (for further details see chapter 1.2). Varying outcome measures, sample 
characteristics, and methodologies can be possible explaining factors for this62,157. A 
better understanding of sex differences is important in order for clinicians to be in a 
position to provide personalized prevention and treatment strategies for both men and 
women with ADHD51,52, e.g. the importance of sex-specific psychiatric comorbidities, 
but also a scientific relevance by providing a better understanding of causation. 
Two studies on sex differences in psychiatric comorbidities have been published after 
paper I was published; another cross-sectional study by Chen and colleagues in 2018, 
and a follow-up/longitudinal study by Ottosen and colleagues, in 2019218,219. Chen and 
colleagues studied adult ADHD and comorbid SUD, BD, depression and anxiety, and 
report somewhat higher prevalence estimates than ours, probably because their sample 
included older individuals (a larger age range of 18-64 compared to our sample of 18-
45), with an increased possibility to be diagnosed with a psychiatric disorder within a 
longer period of time. Therefore, absolute prevalence rates are not directly comparable 
with those in our studies. However, the strongly increased risk of psychiatric 
comorbidity among individuals diagnosed with ADHD was confirmed. The sex 
differences from their study regarding anxiety, depression, BD and SUD were however 
possible to compare, as the male-female ratio of both the cases and non-cases were 
similar to ours, and their results showed the same pattern of sex-specific psychiatric 
comorbidity as in our paper I. 
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Ottosen and colleagues also confirm the higher risk of individuals with ADHD to 
receive a comorbid psychiatric disorder, even if their estimates are not directly 
comparable with our study, as their study has a longitudinal follow-up design. 
However, with a younger population (born 1981-2013 with an age range of 4-32 years), 
many of the individuals with ADHD may not have reached the typical age of onset for 
most psychiatric disorders investigated in paper I. Further, the low female 
representation of 28.2% gives a high male-female ratio of 2.54 (compared to the male-
female ratio of 1.4 in paper I), which obviously influences the relative measures.  
In addition, Ottosen and colleagues’ follow-up design did not include individuals 
receiving a diagnosis of ADHD after one of the comorbid disorders. This is potentially 
a large limitation of the results, as many adults with ADHD in today’s clinical practice 
actually get their ADHD diagnosis after first being diagnosed with another psychiatric 
disorder. However, due to the younger age span of individuals diagnosed with ADHD 
in their study, this may not be such a severe bias. 
Even though Ottosen and colleagues reported that the prevalence of other psychiatric 
disorders was higher in male than in female individuals with ADHD, the associations 
with ADHD were stronger in females than in males on the relative scale, as opposed to 
our findings. This is probably due to the high male-female ratio in their sample and that 
the reference prevalence in females was very low (e.g. 0.5% for ASD and 0.2% for 
ODD/CD).  
In paper I, the sex-specific pattern of psychiatric disorders that we find among adults 
with ADHD is similar to the pattern found in the general population, see Figure 
682,217,220. Further, the absolute prevalence rates are much higher for both men and 
women with ADHD. Although the presence of ADHD enhances the trend between men 
and women in the general population, it is evident that the magnitude of this 
enhancement differs between men and women, and is also dependent on the specific 
disorder. The male-female ratio in our adult ADHD sample is low (papers I & II) 
compared to what is usually reported in studies of ADHD in childhood23, and almost 
the same as in the remaining population (44% females among adults with ADHD and 
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49% females among those without). The finding could rather be interpreted as an 
increased risk of psychiatric disorders in adults with ADHD in general, either mediated 
by common genetic factors between ADHD and the other six psychiatric disorders83, 
by other behavioural traits as a consequence of ADHD (e.g. inattention or 
hyperactivity/impulsivity), or by misclassification/overlapping diagnostic criteria2. 
Risk of psychiatric comorbidity in adults with ADHD or ASD  
In paper II, the sex differences in risk of psychiatric comorbidities were different 
between adults with ADHD or ASD, on both the relative and absolute scales. There 
were no previous population-based studies regarding sex differences in adults with 
ASD or ADHD+ASD to compare our results with.  When stratifying on sex, patterns 
of psychiatric comorbidity corresponded with those in the total sample:  For both men 
and women, prevalence ratio (PR) estimates for SCZ were significantly larger in ASD 
than in ADHD, while for SUD, estimates were significantly larger for ADHD than for 
ASD. The male-female ratio in adults with ASD was higher than in adults with ADHD 
(paper II), and the sex differences in psychiatric comorbidity were not as evident as 
among adults with ADHD. Further, on the relative scale, the prevalence of all (ADHD) 
and three (ASD) psychiatric disorders (anxiety, depression, schizophrenia) increased 
more in men than in women in both exposure groups. When evaluating associations 
and interactions on the additive scale, sex differences were more pronounced, and the 
prevalence difference estimates were significantly different for all disorders in women 
and men with ADHD but for only three disorders (BD, depression, PD) in men and 
women with ASD (Appendix 2 and 3). We suggest that the smaller sex differences 
observed in adults with ASD than ADHD may partly be explained by the larger male-
female ratio in adults with ASD and partly by women with ASD struggling more to 
communicate internalizing symptoms than women with ADHD221. 
Parent-of-origin effects in the recurrence risk of ADHD  
In paper III, we found sex differences in the parent-of-origin effect on recurrence of 
ADHD. The recurrence risk from mother to offspring was stronger than the father-
offspring risk regardless of offspring sex, and regardless of using absolute or relative 
effect measures. A couple of studies support the stronger recurrence of ADHD from 
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mother to offspring than from father to offspring142,143. However, in a large multi-center 
study, Anney and colleagues found that ADHD risk alleles from mothers and fathers 
were equally positively related to ADHD in offspring140. However, none of these 
studies were population-based. In paper III, using the relative scale, recurrence risks 
from mothers and fathers with ADHD were higher in female than in male offspring, 
although the associations from the father were lower than associations from the mother. 
On the absolute scale, the prevalence differences were larger for sons than for daughters 
in all three exposure groups (i.e. father, mother or both parents with ADHD). Further, 
although the prevalence of offspring ADHD was around 1.6 times higher in boys than 
girls regardless of parental ADHD, the difference in prevalence between boys and girls 
was larger in all exposure groups than in offspring to unaffected parents, and largest if 
both parents had ADHD. This may be a true sex difference, or an indication of a 
diagnostic bias towards male offspring due to ADHD symptoms being more descriptive 
for male behaviour51,52.  
Regarding reproduction patterns (for the cohort in MBRN born 1967-1968) in paper 
III, we also found sex differences. Men and women with ADHD were younger when 
they had their first child compared to men and women without ADHD. This finding is 
supported by Ostergaard and colleagues156. Further, the cumulative proportion who had 
at least one child by 2011 in our sample (when the cohort was 43-44 years of age) was 
significantly different between women with and without ADHD (90.4% versus 87.5%, 
p=.017), and between men with and without ADHD (75.2% versus 79.1, p=.007), see 
Figure 8 in chapter 4.3. In other word, and in line with Ostergaards findings, a lower 
proportion of men with than without ADHD ever reproduced. An interesting finding in 
Figure 8 is the crossing of the lines of men with and without ADHD at the age of ~35 
years. Here it seems like men with ADHD reproduce at a younger age, but those who 
have not reproduced by the age of ~35 are less likely than men witout ADHD to 
reproduce at all. We found the opposite for women: a larger proportion of women with 
ADHD reproduced compared to women without. This was contradictory to the study 
by Ostergaard and colleagues, reporting that fewer women with ADHD ever became 
mothers compared to women without156. Our findings may be related how we could 
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define our ADHD cases: individuals being dispensed ADHD medication from 2004 
and/or being registererd with an ADHD diagnosis in the NPR from 2008. The cohort 
of women in the calculation of cumulative reproduction was born 1967-1968, and could 
thus only be included as ADHD cases at the earliest age of 36-37 years. However, a 
replication of this analysis would be of interest. 
We hypothesized that men with ADHD who did not reproduce likely were men with 
more severe ADHD symptoms, while more severe ADHD in women could relatively 
frequently be related to teenage pregnancies. We therefore repeated the analyses, taking 
account of the difference in age at first childbirth between men and women, and then 
also after excluding teenage mothers. These results were in line with the overall results, 
see Figure 9 in chapter 4.3. As an additional sensitivity analysis, we excluded mothers 
with low education (<11 years) instead of teenage mothers as a proxy for severe ADHD 
in women, and the results remained similar (not shown). These sensitivity analyses 
strengthened the conclusions based on our main results. 
Sex differences in psychiatric comorbidities in adults with ADHD and in 
parent-offspring recurrence risk: possible mechanisms 
The sex differences we found in papers I-III are interesting. In all three papers adult 
females with ADHD either had the highest risk of being diagnosed with four of the six 
psychiatric disorders studied (papers I & II), or showed the highest parent-offspring 
recurrence risk of ADHD (paper III). There may be several possible explanations for 
these findings. First, there may be a true difference between males and females caused 
by neurobiological/genetic factors; second, the sex differences in the subjective 
experience of ADHD could influence the risk of other psychiatric disorders; or third, 
the sex difference in health-seeking behavior could influence the risk. A combination 
of these factors is likely.  
A possible true difference between men and women with ADHD which can influence 
the sex difference in risk of other psychiatric disorders, is the putative “female 
protective effect”. A “female protective effect” suggests that females require a greater 
exposure to genetic and/or environmental factors associated with ADHD in order to 
develop the condition (chapter 1.2), (e.g. a higher genetic load)71,72. Sex chromosomes, 
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sex hormones, and gene/environment interactions may influence males and females 
differently46. A higher genetic load suggested in females may also influence the risk of 
other psychiatric disorders as genetic factors are shown to be shared between ADHD 
and other psychiatric disorders83, and this may interact differently in men and women. 
However, due to low sample sizes and lack of representative sex representation in 
GWAS of adults with ADHD, this is not yet studied in adults with ADHD. Due to the 
suggested higher genetic load in females with ADHD, mothers may also have a higher 
transmission risk of ADHD genes to the offspring, compared to fathers with ADHD. 
Further, non-transmitted alleles (environmental effect with a genetic component, 
chapter 1.5.1) may have a larger impact from the mother compared to the non-
transmitted alleles from the father, for instance the stronger nurturing effect from the 
mother on health aspects of the child137.  A combination of these effects is also possible. 
Women with ADHD report more impairment from ADHD symptoms than men23,63,65. 
Women with ADHD also subjectively more often report a negative impact of 
experienced life events compared to men with ADHD (chapter 1.2)222. The larger 
subjective impairment reported in women with ADHD may be linked to a higher rate 
of mood disorders in females. Women both with and without ADHD report more 
depressive symptoms than males52,66. The initiation of pharmacological treatment also 
differs by sex, with later initiation of treatment in females77,223. Both the larger reported 
subjective impairment in females with ADHD, and later initiation of pharmacological 
treatment towards ADHD may increase the risk for adverse outcomes, including 
comorbidities like SUD, depression and suicidal behaviour23,63-65,219,224. Men with 
ADHD are more often diagnosed with the combined ADHD phenotype with more 
externalizing symptoms9,23,52, and the ADHD-associated novelty seeking and 
impulsive behaviour may mediate the risk of developing SUD122. Further, the larger 
risk of schizophrenia in men with ADHD may be related to the larger increase in 
prevalence of SUD, also found in men.  Both having ADHD17,80 and being a male217,225 
increases the risk of SUD, and SUD itself may increase the risk of psychosis226. 
Together, the above-mentioned factors may explain why adult females with ADHD in 
our studies have a higher increase in prevalence of psychiatric disorders like anxiety, 
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depression, BD and PD, compared to men with ADHD, while men with ADHD have a 
higher increase in the prevalence of SUD and SCZ. 
The difference in health-seeking behavior among men and women with ADHD can 
also influence the sex differences we observed in the risk of other psychiatric disorders. 
In general, relatively more females seek health services as adults compared to 
males52,227,228, and by this, they may “catch up” with the males with regards to the 
ADHD diagnosis, explaining the more equal male-female ratio in adulthood52. Contact 
with health service in adulthood is more dependent on self-referral due to own 
experienced symptoms than in childhood, where referral is more dependent on others, 
like parents and teachers51,52 (chapter 1.2). In addition, females seek health-service to 
a larger degree due to reproductive health issues and screening programs (at least in 
Norway). Because of increased contact with health service on a more regular basis 
compared to males, it may be easier for females to ask for help also for psychiatric 
symptoms. All these factors may lead to an increased risk of being diagnosed with 
psychiatric comorbid disorders. Sex differences in health-seeking behavior can also 
partly explain the larger maternal parent-offspring recurrence risk of ADHD, as 
mothers may recognize own symptoms in their children, and seek help with regards to 
both their own and their children’s symptoms52. 
Absolute versus relative scales 
Our main analyses of differences in psychiatric comorbidity by sex in paper I were 
based on effect measures on the absolute scale, supplemented by effect measures on 
the relative scale (see chapter 3.4.2), while results in paper II were based on effect 
measures on the relative scale, supplemented by absolute effect measures when 
assessing sex differences. In paper III, we focused mainly on relative effect measures 
for evaluating parent-offspring recurrence risk.  
The sex differences were dependent on the scale of our effect measures. Effect 
measures on the absolute scale are informative for clinical and public health questions, 
because it may indicate which subgroups need to be prioritized for preventive measures 
and interventions, while effect measures on the relative scale are often used to assess 
 54
the causality aspect190. In our studies, when evaluating the measures on the absolute 
scale, females seem to have the largest burden of ADHD and other psychiatric 
disorders, or at least who seek health service and are registered with these disorders. 
Further, in paper III, also on the absolute scale, sons to parents with ADHD had as 
much as 41.5% risk of ADHD when both parents were diagnosed with ADHD. These 
very high prevalence rates indicate that clinicians are aware of the possibility of ADHD 
in the children of affected parents, and either indicate that boys may be more 
predisposed or that there is a diagnostic bias towards boys. 
Further research is needed to disentangle whether the sex differences in risk of 
psychiatric comorbidity in adults with ADHD and parent-offspring recurrence risk of 
ADHD observed in this study are true sex differences, due to sex differences in self-
experience of ADHD symptoms, due to differences in health-seeking behavior between 
men and women (with ADHD), or a combination of these factors.  
5.2.2 Differences between ADHD and ASD 
One of our aims by comparing risk of psychiatric comorbidities between adults with 
ADHD and ASD (and ADHD+ASD), was to gain knowledge on similarities and/or 
differences that could inform clinicians about the differing risk of psychiatric 
comorbidities, and also inform further research in mechanisms behind these 
neurodevelopmental disorders. In paper II, we chose to compare the pattern of 
psychiatric comorbidities in adults with ADHD, with the corresponding pattern in 
adults with ASD. As described in chapter 1.3.1, ADHD and ASD are both 
neurodevelopmental disorders, often co-occur and share underlying genetic factors97,99-
103. However, even if significant genetic correlations between phenotype-specific traits 
for ADHD and ASD have been demonstrated98,105,106, the phenotypic characteristics for 
these two neurodevelopmental disorders remain quite different3,4,98. Therefore, we 
hypothesized that the pattern of psychiatrc comorbidities could also be different. 
We observed significant differences in the associations with all psychiatric 
comorbidities examined, and with estimates being consistent with previous studies 
17,90,102,107,114,116,122,229. To our knowledge, only one other population-based study 
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reported the prevalence of psychiatric disorders among individuals with ADHD, ASD 
or ADHD+ASD compared with unaffected individuals in the same population123. 
However, this population was young (mean age ranging from 13.6 to 18.3 years) and 
thus had not reached the typical age of onset for most psychiatric disorders82. 
Therefore, the reported estimates were likely biased. 
The high prevalences of psychiatric comorbidities observed both in individuals with 
ADHD, ASD or ADHD+ASD, could reflect that there are “common genetic factors for 
several phenotypic different psychiatric disorders” as recently reported83. Interestingly, 
the most marked differences were found for schizophrenia and SUD, in which 
schizophrenia was more common in adults with ASD and SUD was more common in 
adults with ADHD. The combined group, ADHD+ASD followed the ASD group with 
regards to schizophrenia, but the ADHD group with regards to the other psychiatric 
disorders. Further, the combined group had the strongest associations for several of the 
studied psychiatric disorders, indicating more severe impairment than for ADHD or 
ASD alone107,230,231. Paper III provides robust and representative estimates of 
differences in psychiatric comorbidities among adults diagnosed with ADHD or ASD. 
Together with the results from genetic correlations, these findings contribute to our 
understanding of these disorders as being distinct neurodevelopmental disorders with 
partly shared common genetic factors. Similarities, as well as differences between 
ADHD and ASD, can be further and more specifically evaluated by examining their 
symptom dimensions, each of which may have independent and different explanatory 
values for the clinical diagnoses of ADHD, ASD and their comorbidities98. Both 
diagnostic factors, and behavioural patterns can explain the differences we observe in 
paper III. The distinct comorbidity patterns may provide further information regarding 
etiologic research on biological mechanisms underlying the pathophysiology of these 
neurodevelopmental disorders. 
5.2.1 The “C-word”, a note on causality 
The question of causality in observational studies is important to address. From the first 
preliminary findings of the association between maternal smoking and ADHD in 
offspring to the recent proven causal relation between small for gestational age and 
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ADHD130, there have been several studies showing associations that later have been 
proven to be caused by other factors (e.g. unmeasured confounding153). This 
underscores the challenge in addressing causality in observational data, and emphasizes 
the importance of using proper designs, and preferably a combination of several 
designs (triangulation) 211,232,233. 
The causal relationship between ADHD and other neurodevelopmental or psychiatric 
disorders is difficult to address using registries with a cross-sectional design. However, 
having information about socio-economic covariates (like parental attained education, 
maternal marital status, etc), and perinatal factors (like the individual’s gestational age 
in weeks and gestational age- and sex-specific birthweight z-scores), and parental 
psychiatric disorders, gives the possibility to adjust for possible confounding variables 
that could influence and bias the effect measures. As ADHD is a multi-factorial 
etiological disorder, both genetics and environmental factors are important in the causal 
thinking of ADHD leading to other psychiatric disorders: either mediated by common 
genetic factors, by other behavioural traits as a consequence of ADHD, or by 
misclassification. However, adding genetic correlations between ADHD and ASD and 
other psychiatric traits, and finding of similar patterns, strengthens our results in the 
observational data where we find distinct patterns between adults with ADHD or ASD 
(paper II)211. In paper III, we strengthen our results by using generational data, and 
estimates from data on reproduction which also confirm our first results of higher 
parent-offspring risk from mothers with ADHD. 
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6. Conclusions  
We found evidence for sex differences in adults with ADHD/ASD: 
• Differences in prevalence between adults with and without ADHD were 
significantly larger in women compared to men for all main psychiatric disorders 
except schizophrenia and substance use disorder (SUD), indicating the larger 
potential for introducing preventive measures in women with ADHD. 
• Also, between adults with and without ASD or ADHD+ASD we observed 
significantly larger differences in prevalence in women compared to men for 
several of the studied psychiatric disorders. 
• The present population-based transgenerational study demonstrated a stronger 
recurrence risk of ADHD from mother to offspring than from father to offspring, 
and strongest to female offspring. This was true on both the relative and absolute 
scales.  
 
We found significantly higher risk of psychiatric disorders in adults with ADHD/ASD: 
• Both men and women with ADHD had a 4-9 times higher prevalence of anxiety, 
depression, BD, PD, schizophrenia, and SUD than the remaining adult population. 
• A considerable proportion of cases of anxiety, depression, BD, PD, schizophrenia, 
and SUD in the population can be attributed to an underlying ADHD. 
• In epidemiological data, we found statistically significant differences in risk of 
psychiatric comorbidities between adults diagnosed with ADHD, ASD or 
ADHD+ASD. 
• We found common patterns in differences between ADHD and ASD based on 
genetic and epidemiological data regarding the six psychiatric comorbidities, 
although only two of the studied traits showed statistically significant differences 
between ADHD and ASD. 
• Adults with both ADHD and ASD were more vulnerable to higher levels of 
psychiatric comorbidity. 
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7. Future perspectives 
In this thesis, we have contributed with new knowledge and evidence of sex differences 
in adults with ADHD both in the risk of psychiatric comorbidities and in parent-
offspring recurrence risk. The observed sex differences in papers I-III underline the 
importance of further future research disentangling the contribution of the sex-variable 
in epidemiological data, and in all research where sex is considered relevant. For this 
purpose, both large-scaled GWAS, family data, and the combination of genetic and 
population-based epidemiological data are necessary. It is important to focus on the 
incorporation of relevant theoretical frameworks, adequate representation of both sex 
in study samples, and attention to biases in samples and assessment methods52. 
Khramtsova and colleagues recommend that GWAS of complex traits in the future 
include sex-stratified, gene-by sex interaction, and heritability analyses including sex-
chromosomes to determine the role of sex in the genetic basis of complex traits46. Large 
cohorts of genotyped and phenotyped data, biobanks, population-based registries, and 
associated genomic data, are necessary sources for future studies46. More is also 
necessary to know about the effect of sex hormones, e.g. how menopause affects 
women with ADHD, thus the effect of sex chromosomes/hormones in the development 
and influence on ADHD in a life-course perspective. 
As commented by Turner in an editorial accompanied by the final version of paper II, 
the study provides the field of epidemiology “with a roadmap for the use of comorbidity 
patterns to inform understanding of both overlap and non-overlap of ASD and ADHD 
in a large adult cohort from one country”. In the future to come, epidemiological, 
clinical, and genetic data combined in large population-based datasets will improve the 
understanding of neurodevelopmental and psychiatric disorders and shared factors. 
Further, if it is possible to add information about environmental exposures and social 
determinants, this may contribute to more detailed knowledge about causation and 
personalized interventions234. 
However, our current diagnostic criteria are based on clinically observed aggregates of 
symptoms but may not relate to distinct underlying biological pathways. Hence, well-
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powered GWAS on clearly defined specific psychiatric phenotypes and narrower 
symptom domains are needed to uncover the biological mechanisms underlying the 
multifaceted etiologies of ADHD and ASD. On the contrary, Hyman and colleagues 
argue of the strengths by using broad categories/large groupings/broad clusters of 
diagnostic categories, which confer an advantage and are less likely than individual 
diagnoses to result in artifactual comorbidity235. The use of large groupings/clusters of 
disorders/broad categories of disorders, even with several limitations, is likely to limit 
confounding factors of existing diagnostic categories235. Further, a recent publication 
of cross-disorder GWAS meta-analysis for ADHD, ASD, obsessive-compulsive 
disorder, and Tourette syndrome identified 21 genes significantly associated with these 
conditions, and indicates an increased power in the cross-disorder comparisons236. 
Therefore, a combination of several different strategies may be necessary to 
complement the puzzle of etiological factors contributing to the development of ADHD 
(and other neurodevelopmental disorders). 
In the short term, it is possible to continue to do research based on the existing available 
registry-data, focusing on sex differences. Further, to disentangle the contribution of a 
genetic effect in the parent-offspring effect by sex, enough data to perform GWAS with 
the non-transmitted allele is needed. This may gain insight into pathways through 
which the effect of an individual variant is manifested, and highlights the importance 
of utilizing family/generational data, which is used in paper III137. Thus, it is possible 
to do genetic analyses (polygenic risk scores) in data on parents/trios from 
multigenerational cohorts, such as Avon Longitudinal Study of Parents and Children 
(ALSPAC)237,238 or the Norwegian Mother, Father and Child Cohort Study (MoBa)239, 
to come closer to the observed sex difference in the parent-offspring recurrence risk.  
In the longer run, it is important, although more expensive, to generate large-scaled 
prospective studies, to track males and females through a life-span, and thereby, gain 
knowledge on sex-specific development of ADHD regarding symptoms, prevalence, 
persistence, comorbidities, and adverse life events. Further, in addition to etiological 
research utilizing the epidemiological and genetic data available, it is also important to 
examine the sex difference in health-seeking behavior as an important explanatory 
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factor of the differences in psychiatric diagnoses between men and women. If relevant 
information about health-seeking behavior is available, data from large Norwegian 
health surveys may be utilized for this; the MoBa study, Hordaland Health Studies 
(HUSK)240, and the HUNT Study (an acronym for the Norwegian 
name: Helseundersøkelsen i Nord-Trøndelag)241.  
Related to paper III, more studies using generational data, sibling design, and family 
design with longer follow-up and linking of several registries will increase the 
possibility of going further into the parent-offspring recurrence risk of ADHD, and 
further alleviate the strong associations found in paper III. 
In the question of causal inference/causality regarding psychiatric comorbidities, 
Krieger and Davey Smith have emphasized the use of “triangulation” of different 
designs with different biases and assumptions providing greater confidence in the 
robustness of the results233. 
Our understanding of the etiology and pathogenesis of ADHD is still limited. The main 
aim of the research should always be to the best of individuals with ADHD, toward 
personalized and ultimately precision medicine. Also, to better focus on a lifespan 
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Appendix 1. Overview of the different parent-offspring recurrence analyses (A, C) and calculation of 









Appendix 2. Prevalence difference of psychiatric disorders in adults with ADHD, ASD and 









Abbreviations: Schizophrenia= Schizophrenia Spectrum Disorder, SUD= Substance Use Disorder, 
BD= Bipolar Disorder, MDD= Major Depression Disorder, PD= Personality Disorder. Prevalence 
difference, 95% CI error bars, analogue scale. Adjusted for birth year (5-year groups, from 1967 to 
1997).  
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Appendix 3. Reprinted with permission from Elsevier. Turner TN. Large-Scale Population-Based 
Assessment of Psychiatric Comorbidities in Autism Spectrum Disorder and Attention-




































Gender differences in psychiatric
comorbidity: a population-based study of
40 000 adults with attention deficit
hyperactivity disorder
Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K.
Gender differences in psychiatric comorbidity: a population-based
study of 40 000 adults with attention deficit hyperactivity disorder.
Objective: We aimed at determining whether gender modified
associations between ADHD and psychiatric comorbidities in adults.
Method: We identified adults with ADHD by linking Norwegian
national registries and compared them with the remaining adult
population (born 1967–1997, ADHD and bipolar during 2004–2015,
other psychiatric disorders 2008–2015). Prevalence differences (PDs)
and prevalence ratios (PRs) of psychiatric disorders were determined by
Poisson regression. Interaction by gender was evaluated on additive
(PDs) and multiplicative (PRs) scales. Proportions of psychiatric
disorders attributable to ADHD were calculated.
Results: We identified 40 103 adults with ADHD (44% women) and
1 661 103 adults (49% women) in the remaining population. PDs
associated with ADHD were significantly larger in women than in
men for anxiety, depression, bipolar and personality disorders, for
example depression in women: 24.4 (95% CI, 23.8–24.9) vs. in men:
13.1 (12.8–13.4). PDs were significantly larger in men for schizophrenia
and substance use disorder (SUD), for example SUD in men:
23.0 (22.5–23.5) vs. in women: 13.7 (13.3–14.0). Between 5.6 and 16.5% of
psychiatric disorders in the population were attributable to ADHD.
Conclusion: The association between ADHD and psychiatric
comorbidities differed significantly among men and women. Clinicians
treating adults with ADHD should be aware of these frequent and
gender-specific comorbidities, such that early treatment can be offered.
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Significant outcomes
• Both men and women with ADHD had a 4–9 times higher prevalence of anxiety, depression, bipolar
and personality disorders, schizophrenia and substance use disorder (SUD) than the remaining adult
population.
• Differences in prevalence between ADHD and non-ADHD adults were significantly larger in women
than in men for all psychiatric disorders except schizophrenia and SUD, indicating the larger poten-
tial for introducing preventive measures in women with ADHD.
• A considerable proportion of cases of anxiety, depression, bipolar and personality disorders,
schizophrenia and SUD in the population can be attributed to an underlying comorbid ADHD.
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• This study employed a cross-sectional design, limiting the possibility of making causal conclusions.
• Information on ADHD and psychiatric comorbid disorders was based on data registered in the Nor-
wegian Prescription Database from 2004 to 2015 and in the Norwegian Patient Registry from 2008 to
2015, limiting the study of temporal relations.
• Information on psychiatric comorbid disorders was based on diagnoses registered in secondary
health care, missing comorbidities registered in primary care.
Introduction
Attention deficit hyperactivity disorder (ADHD)
(1, 2) is an impairing and prevalent childhood-
onset disorder that frequently persists into adult-
hood (3–5). Based on an estimated worldwide
prevalence of 2.5% among adults, ADHD affects
millions of individuals across the world and is of
major public health concern (3, 6, 7). The strong
male predominance among children with ADHD
decreases with age; further, comorbidity with
other psychiatric disorders is the rule rather than
the exception, particularly in adults with ADHD
(8–12). It is also known that women with
ADHD are more frequently diagnosed with the
inattentive subtype, as defined in DSM-IV/DSM-
5 (1, 13), with more internalizing comorbid dis-
orders such as depression and anxiety. Women
also report more impairment than men (11, 14–
17), and a study based on self-reports among
adults showed that women with ADHD, more
often than men, reported a history of treatment
for other psychiatric disorders than ADHD (8).
The combined subtype, with more externalizing
symptoms, is more frequent in men (17). This
subtype is more often linked to antisocial per-
sonality disorder and substance use disorder
(SUD) (11, 18).
Several studies have focused on psychiatric
comorbidity in adults with ADHD, for example
anxiety and major depressive disorder (depression)
(3, 11), bipolar disorder (9–11, 19), personality dis-
orders (20, 21), schizophrenia spectrum disorders
(schizophrenia) (19, 22, 23) and SUD (11, 24).
However, existing studies of gender differences in
such comorbidity have shown conflicting results in
adults with ADHD, possibly because of varying
outcome measures, sample characteristics and
methodologies. To gain a better understanding of
gender differences is important in order to be in a
position to provide suitable treatment and preven-
tion strategies for both men and women with
ADHD (18, 25). Few studies have investigated
whether these comorbidities differ between men
and women (26, 27), and large epidemiological
studies of good quality are still lacking (7, 18).
In the present work, we use the term ‘gender’
instead of ‘sex’ because the study concerns adults,
and ‘gender’ is shaped by environment and experi-
ence in addition to the biological characteristics
determined by sex (28).
Aims of the study
We aimed at determining whether gender modified
associations between ADHD and psychiatric
comorbidities. We also aimed at determining the
proportion of psychiatric disorders among men
and women in the population that could be attrib-
uted to a comorbid ADHD.
Method
Study population
We conducted a cross-sectional analysis in a
cohort of adults in Norway, by linking information
from four nationwide, population-based registries:
The Medical Birth Registry of Norway (MBRN),
established in 1967 (29), the Norwegian Prescrip-
tion Database (NorPD) (30), established in 2004,
the Norwegian Patient Registry (NPR) (31), with
data from 2008, and the National Educational
Database (NUDB) from Statistics Norway (32,
33). See Appendix S1 for Supporting Information
and details about the registries. The study included
all individuals born between 1967 and 1997, alive
and resident in Norway at record linkage in 2015
(n = 1 701 206). Record linkage was established
using the national identification number unique to
every Norwegian resident.
The study was approved by the Regional Ethics
Committee in Norway (2011/2272). No informed
consent was required for the analysis of anon-
ymized registry data.
We defined adults with ADHD as those who
had been dispensed their last prescription of
ADHD medication at 18 years of age or more
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during 2004–2015 (NorPD), or with an ADHD
diagnosis registered at 18 years or higher in the
period 2008–2015 (NPR). The ADHD medications
identified were the central stimulants: methylpheni-
date, racaemic amphetamine and dexamphet-
amine, and the non-stimulant drug atomoxetine,
see Appendix S2 for ADHD medication used for
narcolepsy.
The remaining population included all adults
(18 years or older by record linkage) who had nei-
ther been dispensed ADHD medication nor had an
ADHD diagnosis, in the NorPD and NPR respec-
tively. Parents to adults with and without ADHD
were also identified through the MBRN, to evalu-
ate the influence of factors known to be associated
with both ADHD and other psychiatric disorders
(sociodemographic variables, pregnancy-related
risk factors and parental psychiatric disorders).
Measures
We analysed the association between ADHD and
psychiatric disorders among men and women,
ADHD being our ‘exposure’, and evaluated effect
modification by gender. Our main aim was to eval-
uate psychiatric comorbidity in adults with
ADHD, and for this analysis, no confounding
variables are relevant; thus, we only adjusted for
age (birth year; 5-year groups from 1967 to 1997,
with 1967–1973 as the reference period). To evalu-
ate how risk factors for both ADHD and other
psychiatric disorders influenced the prevalence
ratios, we ran two regression models, including the
following covariates that all have been docu-
mented as risk factors for ADHD and psychiatric
disorders (34–41): Model 1: birth year, maternal
marital status (single, married/cohabiting (refer-
ence category), other), maternal age (<20, 20–24,
25–29 (reference value), 30–34, 35–39, 40+) and
paternal age (<20, 20–24, 25–29, 30–34 (reference
value), 35–39, 40–44, 45–49, 50+) at delivery, par-
ent’s highest attained educational level at record
linkage (low (<10 years of education), middle (10–
12 years of education) and high level (>12 years of
education (reference category)), the individual’s
gestational age in weeks (<27, 28–31, 32–34, 35–36,
37–41 (reference value), 42+) and gestational age-
and sex-specific birthweight z-scores (<-2.0; 2.0
to 0.51; 0.5 to 0.5 (reference value); 0.51 to 2.0;
2.01+).
Model 2 further included mothers’ and fathers’
psychiatric diagnoses (yes/no), including ADHD
or any other psychiatric diagnosis from NPR,
2008–2015.
We studied the following major comorbid psy-
chiatric disorders, typically diagnosed in late
adolescence and adulthood, and all registered at
18 years or more: anxiety (ICD-10 codes; F40-
F42), depression (F32-F33), bipolar (F30-F31) and
personality disorders (F60-F61), schizophrenia
(F20-F29) and SUD (F10-F19).
To define bipolar disorder, we used data from
the NorPD in addition to the NPR including indi-
viduals who had been prescribed and dispensed
either lithium during 2004–2015 or anti-epileptic
drugs with mood disorders as the indication during
2008–2015 (indications for psychotropic medica-
tions are only available in the NorPD since 2008).
Statistical analysis
Absolute prevalence differences (PD) of psychiatric
disorders between persons with and without
ADHD among men and women were calculated
using predicted prevalences from a Poisson regres-
sion model with adjustment for birth year (5-year
periods). Significance of interaction by gender on
the additive scale was evaluated using relative
excess risk due to interaction (RERI) (42). While it
has been suggested that effect measures and inter-
actions on the multiplicative scale are better suited
to ‘assess causality’, risk differences and interac-
tions on the additive scale are the most important
to assess public health relevance, indicating which
group may benefit the most from treatment or pre-
ventive measures (42). To examine the association
between ADHD and other psychiatric disorders
on a multiplicative scale, we estimated prevalence
ratios (PR) using Poisson regression with robust
standard errors (43). Significance of interaction by
gender on the multiplicative scale was evaluated by
comparing Poisson regression models with and
without the interaction term (gender x ADHD)
included, as tested by likelihood ratio tests.
Finally, we estimated the proportion of psychiatric
comorbidities attributable to ADHD among men
and women with ADHD (attributable fractions in
the exposed—AFE) and in the population (popu-
lation attributable fractions—PAF) (44). Two-
sided tests with a significance level of 0.05 were
used in all analyses. Analyses were carried out with
PASW Statistics 23 (45) and STATA intercooled
v.14 (46) from 3 January 2016 to 24 July 2017.
Sensitivity analysis
We conducted several sensitivity analyses to test
the robustness of the results, see Appendix S3 in
Supporting Information for details: for all psychi-
atric disorders, we excluded individuals with a
diagnosis of mental retardation, and when analys-
ing prevalences of bipolar disorder, we excluded
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individuals with comorbid schizophrenia. We
repeated analyses including only individuals with
one psychiatric comorbid diagnosis alone. Analy-
ses were also repeated requiring the psychiatric
diagnosis to be registered at least twice in the
NPR. Finally, when adjusting for covariates, we
used multiple imputation with chained equations
(MICE) (47) to evaluate possible biases due to
missing information for gestational age. In the
main analyses, missing values in covariates (6%
for gestational age and birthweight z-scores, other
variables <1%) were handled by listwise deletion.
To impute for missing values in gestational age
and z-scores, we ran sensitivity analyses using
MICE, where the outcome variables, all specified
covariates and also birthweight, maternal preecl-
ampsia and mother’s chronic diseases (yes/no),
were used for information.
Results
Study groups
We identified a total of 40 103 adults with ADHD
(2.4% of the population), 17 815 women (44.4%),
with a total mean age of 31 years in 2015. The
remaining population consisted of 1 661 103
adults, 812 061 women (48.9%) and a mean age
for the total sample of 33 years in 2015. The
male : female ratio in the ADHD group was
1.3 : 1. As shown in Table 1, more mothers of
ADHD adults than remaining mothers had the
lowest educational level (34.9% vs. 26.2%) and
were single when giving birth (16.8% vs. 9.2%).
Also, parents of ADHD adults had significantly
more psychiatric disorders than parents of the
remaining population (mothers: 27.3 vs. 13.4%;
fathers: 17.3 vs. 9.9%).










No. (%) 40 103 (2.4) 1 661 103 (97.6) 17 815 (44.4) 22 288 (55.6)
Gender
Women 17 815 (44.4) 812 061 (48.9)
Men 22 288 (55.6) 849 042 (51.1)
M:F ratio 1.25 1.05
Mean age in 2015 (years) (SD) P < 0.001* P < 0.001**
31.2 (8.3) 33.1 (9.3) 31.4 (8.4) 31.0 (8.2)
Gestational age (weeks) P < 0.001* P < 0.001**
<27 113 (0.3) 2464 (0.2) 43 (0.3) 70 (0.3)
28–31 283 (0.8) 7835 (0.5) 101 (0.6) 182 (0.9)
32–34 677 (1.9) 22 239 (1.4) 270 (1.7) 407 (2.0)
35–36 1313 (3.6) 49 624 (3.2) 532 (3.3) 781 (3.8)
37–41 28 552 (77.9) 1 250 422 (80.3) 12 660 (77.8) 15 892 (78.1)
42+ 5701 (15.6) 223 779 (14.4) 2661 (16.4) 3040 (14.9)
Missing 3464 (8.6) 104 740 (6.3) 1548 (8.7) 1916 (8.6)
Maternal marital status P < 0.001* P = 0.9**
Married/cohabitant 32 342 (80.9) 1 489 193 (89.8) 14 354 (80.8) 17 988 (80.9)
Single 6708 (16.8) 152 884 (9.2) 2996 (16.9) 3712 (16.7)
Other 944 (2.4) 16 250 (1.0) 419 (2.4) 525 (2.4)
Missing 109 (0.3) 2776 (0.2) 46 (0.3) 63 (0.3)
Maternal educational status P < 0.001* P = 0.8**
Low 13 892 (34.9) 432 778 (26.2) 6197 (35.0) 7695 (34.7)
Middle 17 061 (42.8) 771 795 (46.7) 7629 (43.1) 9432 (42.6)
High 8903 (22.3) 449 945 (27.2) 3877 (21.2) 5026 (22.7)
Missing 247 (0.6) 6585 (0.4) 112 (0.6) 135 (0.6)
Paternal educational status P < 0.001* P = 0.006**
Low 12 889 (33.0) 382 793 (23.4) 5695 (32.8) 7194 (33.2)
Middle 19 320 (49.5) 838 027 (51.2) 8746 (50.4) 10 574 (48.8)
High 6827 (17.5) 416 636 (25.4) 2914 (16.8) 3913 (18.1)
Missing 1067 (2.7) 23 647 (1.4) 460 (2.6) 607 (2.7)
Maternal psychiatric disorder P < 0.001* P = 0.99**
None 29 149 (72.7) 1 437 851 (86.6) 12 977 (72.8) 16 172 (72.6)
Any, including ADHD 10 953 (27.3) 223 216 (13.4) 4838 (27.2) 6115 (27.4)
Paternal psychiatric disorder P < 0.001* P = 0.06**
None 32 667 (82.7) 1 485 656 (90.1) 14 609 (83.2) 18 058 (82.2)
Any, including ADHD 6848 (17.3) 162 779 (9.9) 2941 (16.8) 3907 (17.8)
*P-value (Pearson’s chi-square test and t-test for equality of means) for the difference in ADHD total relative to the comparison population.
**P-value (Pearson’s chi-square test and t-test for equality of means) for the difference in men with ADHD vs. women with ADHD.
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Association between ADHD and psychiatric comorbidities in men
and women
Adults with ADHD had a much higher prevalence
of additional psychiatric disorders compared to the
remaining population, as shown in Fig. 1. As many
as 53.5% of women and 48.5% of men with ADHD
had one or more of the six studied psychiatric
comorbidities, compared to 13.7% of women and
9.1% of men in the remaining population. Women
with ADHD had the highest prevalence of all disor-
ders except schizophrenia and SUD (Fig. 1).
Evaluated on an absolute scale, the prevalence
differences (PD) between adults with and without
ADHD were statistically significant for all the psy-
chiatric disorders and ranged from 2.1% (95% CI
2.0–2.3) for schizophrenia to 24.4% (23.8–24.9) for
depression, both in women, see Table 2.
Evaluated on a multiplicative scale, adult ADHD
was most closely associated with bipolar disorder,
personality disorders and SUD, with PR estimates
ranging from 7.2 (95% CI, 7.0–7.5) for SUD in
women to 8.9 (8.5–9.3) for bipolar and personality
disorders in men. Associations with anxiety, depres-
sion and schizophrenia were weaker, though still
strong, with a four to five times higher prevalence of
these disorders in both men and women with
ADHD than those without, see Table 3.
Interaction by gender
Interaction by gender was tested both on the addi-
tive and the multiplicative scales, see Tables 2 and
3. When testing for interaction by gender on an
additive scale, the PDs were significantly larger in
women than in men for all psychiatric comorbidi-
ties except schizophrenia and SUD, where the PDs
were larger in men. On the multiplicative scale, the
associations with ADHD were significantly stron-
ger in men than in women for anxiety, depression,
bipolar and personality disorders, see Table 3.
Attributable proportions
A large proportion of psychiatric disorders among
adults with ADHD could be attributed to their
existing ADHD condition, with AFE ranging from
72.9% to 87.5% in women and 79.5% to 88.8% in
men, see Table 3. The proportions of psychiatric
disorders in the adult population that could be
attributed to a comorbid ADHD were also high,
with PAF ranging from 5.6% to 13.0% in women
and from 8.9% to 16.5% in men.
Sensitivity analysis
The results of the sensitivity analyses are shown in
Supporting Information, Tables S1–S3. All sensi-
tivity analyses were compatible with the results of
the main analyses.
Discussion
This is the first large population-based study per-
formed on adults clinically diagnosed with ADHD
to evaluate gender differences in major psychiatric



































Fig. 1. Adjusted* prevalences of psychiatric disorders in men and women with and without ADHD. *Prevalences was adjusted for
birth year, 5-year groups, from 1967 to 1997, with 1967–1973 as the reference. SUD, Substance use disorder.
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Table 2. Prevalence differences in psychiatric disorders in men and women with and without ADHD. Effect modification by gender evaluated on an additive scale
Psychiatric disorders (ICD-10)
Crude prevalences, No. (%) Prevalence, % (95% CI)*
Additive effect modification†
ADHD Non-ADHD ADHD Non-ADHD PD‡ (95% CI) RERI§ (95% CI)
Anxiety disorders (F40–42)
Women 4676 (26.3) 54 479 (6.7) 28.7 (28.2–29.3) 6.6 (6.6–6.7) 22.1 (21.6–22.6) 1.4 (1.2–1.7)*¶
Men 4054 (18.2) 28 364 (3.3) 14.8 (14.5–15.1) 3.4 (3.4–3.5) 11.4 (11.1–11.7)
Bipolar disorder (F30–31 or medication)k
Women 2290 (12.9) 13 183 (1.6) 13.5 (13.1–13.9) 1.6 (1.6–1.6) 11.9 (11.5–12.3) 3.4 (2.7–4.0)*
Men 1981 (8.9) 9009 (1.1) 8.9 (8.7–9.2) 1.1 (1.0–1.1) 7.9 (7.6–8.1)
Major depressive disorder (F32–33)
Women 5138 (28.8) 61 880 (7.6) 31.9 (31.4–32.5) 7.5 (7.5–7.6) 24.4 (23.8–24.9) 1.3 (1.1–1.5)*
Men 4516 (20.3) 33 733 (4.0) 17.1 (16.8–17.5) 4.1 (4.0–4.1) 13.1 (12.8–13.4)
Personality disorder (F60–61)
Women 2428 (13.6) 14 079 (1.7) 14.0 (13.6–14.5) 1.7 (1.7–1.7) 12.3 (11.9–12.7) 3.8 (3.2–4.4)*
Men 2030 (9.1) 8909 (1.1) 8.7 (8.4–8.9) 1.1 (1.0–1.1) 7.6 (7.3–7.9)
Schizophrenia spectrum disorder (F20–29)
Women 444 (2.5) 4621 (0.6) 2.7 (2.5–2.8) 0.6 (0.5–0.6) 2.1 (2.0–2.3) 1.8 (2.2; 1.3)*
Men 928 (4.2) 7352 (0.9) 4.1 (3.9–4.3) 0.9 (0.8–0.9) 3.3 (3.0–3.5)
Substance use disorder (F10–19)
Women 2878 (16.2) 17 200 (2.1) 15.8 (15.4–16.1) 2.1 (2.1–2.1) 13.7 (13.3–14.0) 2.9 (3.1; 2.7)*
Men 6135 (27.5) 30 233 (3.6) 26.6 (26.1–27.1) 3.6 (3.5–3.6) 23.0 (22.5–23.5)
ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision, World Health Organization; CI, confidence interval; PD, prevalence differ-
ence; RERI, relative excess in risk due to interaction.
*Prevalence adjusted for birth year (5-year groups, from 1967 to 1997, with 1967–1973 as the reference period).
†Female gender as reference group.
‡Prevalence Difference (PD) between adults with and without ADHD, adjusted for birth year as above.
§Relative Excess in Risk due to Interaction (RERI) adjusted for birth year as above.
¶P-value of interaction on an additive scale, all P < 0.001.
kMedication: lithium during 2004–2015 or anti-epileptic drugs with mood disorders as the indication during 2008–2015.
Table 3. Prevalence ratios of psychiatric disorders men and women with and without ADHD. Effect modification by gender evaluated on a multiplicative scale
Psychiatric disorders
Crude prevalences, No. (%) Prevalence ratios (95% CI) Attributable fraction (95% CI)
ADHD Non-ADHD Crude† Model 1‡ Model 2§ AFE¶ PAFk
Anxiety Disorders P < 0.001** P < 0.001 P < 0.001 ††
Women 4676 (26.3) 54 479 (6.7) 3.7 (3.7–3.8) 3.6 (3.5–3.7) 3.4 (3.3–3.5) 73.3 (72.6–74.0) 5.8 (5.6–6.0)
Men 4054 (18.2) 28 364 (3.3) 5.3 (5.2–5.5) 5.1 (4.9–5.2) 4.7 (4.5–4.8) 81.2 (80.6–81.7) 10.2 (9.8–10.5)
Bipolar Disorder P = 0.03 P = 0.03 P = 0.07
Women 2290 (12.9) 13 183 (1.6) 8.0 (7.7–8.3) 7.8 (7.5–8.2) 7.2 (6.8–7.5) 87.5 (87.0–88.0) 13.0 (12.4–13.5)
Men 1981 (8.9) 9009 (1.1) 8.9 (8.5–9.3) 8.9 (8.5–9.4) 8.1 (7.7–8.5) 88.8 (88.2–89.3) 16.0 (15.3–16.7)
Major depressive disorder P < 0.001 P < 0.001 P < 0.001
Women 5138 (28.8) 61 880 (7.6) 3.7 (3.6–3.8) 3.6 (3.5–3.7) 3.3 (3.2–3.4) 72.9 (72.2–73.5) 5.6 (5.4–5.8)
Men 4516 (20.3) 33 733 (4.0) 5.1 (5.0–5.3) 4.9 (4.8–5.0) 4.5 (4.4–4.6) 80.5 (79.9–81.0) 9.5 (9.2–9.8)
Personality disorder P = 0.001 P = 0.008 P = 0.02
Women 2428 (13.6) 14 079 (1.7) 7.7 (7.3–8.0) 7.1 (6.8–7.4) 6.5 (6.2–6.8) 86.9 (86.4–87.5) 12.8 (12.3–13.3)
Men 2030 (9.1) 8909 (1.1) 8.9 (8.5–9.3) 8.1 (7.7–8.5) 7.3 (6.9–7.7) 88.8 (88.2–89.3) 16.5 (15.8–17.2)
Schizophrenia spectrum disorder P = 0.08 P = 0.07 P = 0.1
Women 444 (2.5) 4621 (0.6) 4.5 (4.1–4.9) 4.5 (4.1–5.0) 4.1 (3.7–4.6) 77.7 (75.4–79.7) 6.8 (6.0–7.6)
Men 928 (4.2) 7352 (0.9) 4.9 (4.6–5.2) 4.8 (4.5–5.2) 4.3 (4.0–4.7) 79.5 (78.0–80.8) 8.9 (8.2–9.6)
Substance use disorder P = 0.4 P = 0.7 P = 0.98
Women 2878 (16.2) 17 200 (2.1) 7.2 (7.0–7.5) 6.3 (6.1–6.6) 5.8 (5.6–6.0) 86.2 (85.7–86.7) 12.4 (11.9–12.8)
Men 6135 (27.5) 30 233 (3.6) 7.6 (7.4–7.8) 6.6 (6.5–6.8) 6.1 (6.0–6.3) 86.8 (86.5–87.1) 14.6 (14.3–15.0)
CI, Confidence interval; ADHD, adults with ADHD; non-ADHD, remaining population without ADHD; AFE, attributable fraction among the exposed; PAF, population attributable fraction.
†Adjusted for birth year (5-year groups from 1967 to 1997, with 1967–1973 as the reference period).
‡Model 1: Adjusted for birth year, maternal marital status (single, married/cohabiting (reference category), other), maternal and paternal education (low (<10 years of education),
middle (10–12 years of education and high level (>12 years of education (reference category)), maternal age (<20, 20–24, 25–29 (reference value), 30–34, 35–39, 40+) and
paternal age (<20, 20–24, 25–29, 30–34 (reference value), 35–39, 40–44, 45–49, 50+) at delivery, gestational age (<27, 28–31, 32–34, 35–36, 37–41 (reference value), 42+),
gestational age and sex-specific birthweight z-scores (<2.0; 2.0 to 0.51; 0.5 to 0.5 (reference value); 0.51–2.0; 2.01+).
§Model 2: As in Model 1 and additionally adjusted for maternal and paternal psychiatric disorders (yes/no).
¶Attributable fraction among the exposed (AFE) (%) (=ADHD population), based on crude model.
kPopulation attributable fraction (PAF) (%), based on crude model.
**P-value of the interaction between ADHD and sex on a multiplicative scale.
††Statistical significant difference between men and women with ADHD based on non-overlapping 95% confidence intervals.
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on both multiplicative and additive scales. Both
men and women with ADHD had 4–9 times higher
prevalences of all the studied psychiatric disorders
than the remaining adult population. However, on
an absolute scale, differences in prevalence between
ADHD and non-ADHD adults were significantly
larger in women than in men for all psychiatric dis-
orders except schizophrenia and SUD, indicating
the larger potential for preventive measures in
women with ADHD. The proportions of psychi-
atric disorders in the population attributable to a
comorbid ADHD were large for both genders.
In line with previous studies in the literature, we
found higher prevalences of all the studied comor-
bidities in adults with ADHD than in those with-
out (3, 10). However, few previous studies have
evaluated gender differences in comorbidity among
adults with ADHD, and results from existing stud-
ies are conflicting. A study of 219 clinically diag-
nosed adults with ADHD, including 37.4%
women, found no gender difference in risk of anxi-
ety, bipolar disorder, depression, SUD and antiso-
cial personality disorder, but that study was in all
likelihood underpowered (11). One of the largest
population-based studies until now, a twin-study
using self-reported symptom scores for both
ADHD and other psychiatric disorders, studied
anxiety, bipolar disorder, depression and alcohol
dependence. Similar relative risk estimates for anx-
iety and bipolar disorder as in our study were
reported, but gender differences were not found
(26). In another recent twin-study based on self-
reported symptom scores, a high risk of comorbid
SUD in adults with ADHD was reported, but this
did not report finding any gender differences (24).
Among studies showing high risk of comorbid
bipolar disorder, one was large and population-
based, but involved both children and adults (19);
another study was small with low female represen-
tation (11). Both studies considered gender differ-
ences, but none were found. A large Swedish study
analysed risk of comorbid schizophrenia, but did
not focus on adults and did not evaluate gender
differences (19). A smaller Danish study found the
same relative risk of comorbid psychosis as
observed here, but in adults diagnosed with
ADHD as children. The study only included a
small proportion of women, and an evaluation of
gender differences was thus not possible (22). A
large study from Taiwan with over 70 000 individ-
uals with ADHD diagnosed in childhood reported
a five times higher risk of developing some form of
psychotic disorder. The male proportion was 80%,
and mean age at diagnosed psychosis was only
15 years. An increased risk for psychosis in women
with ADHD was, however, found (23). The
number of studies on ADHD and different person-
ality disorders is smaller and mostly performed on
young adults and adolescents, where ADHD was
diagnosed in childhood. Hazard ratios of 5.8 for
personality disorders ‘not specified’ and 3.1 for
antisocial personality disorder have been reported
without specification of gender (21, 48).
Most previous studies have their limitations:
they have either relied on self-reported diagnosis of
ADHD diagnosis or screening questionnaires,
many studies are small, and most of them have a
low proportion of females or include individuals
younger than 18 years at the time of comorbid
diagnosis. Few studies have been population-based
or focused specifically on gender differences in risk
of comorbidities in adults.
In a recent narrative meta-analysis of gender dif-
ferences in adult ADHD, Williamson and John-
ston found that only three of 11 studies included
appropriate comparison groups (18). However, the
most important difference, and novelty of the pre-
sent study, is that we tested for interaction by gen-
der on an additive scale, thus using the prevalence
differences to estimate the prevention potential.
We also calculated the proportion of major psychi-
atric disorders that could be attributed to ADHD
in the adult population.
Testing for interaction on the additive scale is
informative for clinical and public health ques-
tions, because it may indicate which subgroups
need to be prioritized such that preventive mea-
sures and interventions can be introduced (42). We
found that differences in prevalences of anxiety,
depression, bipolar and personality disorders
between adults with and without ADHD were sig-
nificantly larger for women than for men, while the
opposite was true for SUD and schizophrenia. Pre-
vious investigations have failed to show these gen-
der differences in psychiatric comorbidities, and
none have evaluated interactions on an additive
scale. Women with ADHD have been shown to
report more symptoms and impairments resulting
from their condition than men, thus possibly pre-
disposing them to a higher level of psychiatric
comorbidity (11, 14–16, 49). Our results show that
there is a relatively higher increase in prevalence of
most psychiatric comorbidities associated with
ADHD in women with ADHD fitting this. Detect-
ing and treating ADHD in girls and women may
prove to be an important preventive measure in
order to reduce the risk of future psychiatric
comorbidity. Paying more attention towards girls
and women with ADHD, who have less hyperac-
tivity and therefore may go undiagnosed during
childhood years, may thus be warranted, both
among clinicians and researchers (25). The larger
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increase in SUD and schizophrenia associated with
ADHD in men is also of importance, and clini-
cians treating adults with ADHD should be aware
of the gender-specific comorbidities described in
our study, both with respect to detection and the
offer of early treatment following diagnosis.
The larger increase in prevalence of schizophre-
nia associated with ADHD in men might be
related to the larger increase in prevalence of SUD,
also found in men. Both having ADHD (10, 24)
and being a male (50, 51) increase the risk of SUD,
and SUD itself may increase the risk of psychosis
(52). To test this hypothesis, we excluded all indi-
viduals with SUD in the study population
(n = 62 434) and reran the PD analyses for
schizophrenia. The PDs of schizophrenia in
women with and without ADHD changed from
2.1 (95% CI, 2.1–2.1) to 1.1 (1.0–1.3) and in men
from 3.3 (3.0–3.5) to 1.4 (1.2–1.6). The gender dif-
ference was still statistically significant (RERI
0.66, 95% CI, 1.3 – 0.07). We therefore
believe that the increased risk of schizophrenia in
men with ADHD may be partly, although not fully
explained, by a comorbid SUD. The apparent
increased vulnerability to schizophrenia in men
with ADHD could be of clinical importance. In
contrast, when excluding all cases with SUD, the
PD for women was no longer significant when
compared to women without ADHD.
The relatively increased risk of anxiety and
depression in men with ADHD on the multiplica-
tive scale may partly be explained by the low
prevalence of these disorders in men without
ADHD, who generally have lower health-seeking
behaviour (53). Men with ADHD are already in
contact with the health services and may therefore
get these comorbid disorders diagnosed more
easily than their non-ADHD counterparts.
Although both men and women with ADHD are
in contact with the health services, women, inde-
pendently of ADHD, are generally in closer con-
tact with the health services than men, due to, for
example, maternal health issues (fertility regula-
tion, pregnancy and childbirth) (54). This may
partly explain why disorders such as depression
and anxiety are more easily detected in women
than in men in the general population (50, 55).
The gender-specific pattern of psychiatric disor-
ders that we find among adults with ADHD in our
study is similar to the pattern found in the general
population (50, 51, 56). The absolute prevalence
rates are, however, much higher for both men and
women with ADHD, as shown in Fig. 1. Although
the presence of ADHD enhances the trend among
men and women in the general population, it is evi-
dent that the magnitude of this enhancement
differs between men and women and is also depen-
dent on the specific disorder.
To evaluate how associations between ADHD
and psychiatric comorbidities were influenced by
common risk factors for both ADHD and other
psychiatric disorders, we adjusted for socioeco-
nomic and perinatal risk factors (Model 1). This
hardly changed the PR estimates. When also
including psychiatric disorders of the parents in
the model (Model 2), the estimates were slightly
attenuated, suggesting that genetic predisposition
or problems linked to having parents suffering
from psychiatric diseases are important, see
Table 3. This calls for increased attention regard-
ing children of parents being treated for psychiatric
disorders.
Strengths and limitations
Our study has several strengths. We used data
from nationwide health registries of good quality
and with mandatory, prospective reporting, mini-
mizing selection bias and loss to follow-up and
eliminating recall bias. Bipolar disorder and
schizophrenia registration in the NPR have been
validated with good results (31). Due to the large
study population with almost 45% women with
ADHD, we could evaluate less prevalent disorders,
such as schizophrenia, and compare psychiatric
comorbidity in men and women with representa-
tive numbers in both groups. We had prospectively
registered data on perinatal factors (birthweight
and gestational age) for the whole study popula-
tion, and we had information on psychiatric diag-
noses, including ADHD, for the parents.
Therefore, we could adjust for these covariates to
evaluate whether these risk factors explained the
increased prevalence of psychiatric comorbidities
in adults with ADHD.
Unlike some other large Scandinavian popula-
tion-based studies, we did not use ADHD symp-
tom ratings or self-reports to define ADHD.
ADHD medication is restricted in Norway, and
medical treatment in adults is initiated only after
thorough assessment by a specialist in psychology
or psychiatry. Therefore, we believe that a pre-
scribed and dispensed prescription of ADHD med-
ication is a good proxy for a clinical ADHD
diagnosis. Calculating PDs and testing for interac-
tion by gender on the additive scale give relevant
information concerning which comorbid diagnoses
clinicians should be especially aware of when
following men and women with ADHD. Our
estimates of attributable risk of comorbid disor-
ders in men and women with ADHD underscore
the gender-specific prevention potential.
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We are aware that our study also has some limi-
tations: analyses were cross-sectional and based on
data registered in the NorPD from 2004–15 and in
the NPR from 2008–15, limiting the study of tem-
poral relations. However, as ADHD is defined as a
neuropsychiatric disorder with onset in childhood,
we may assume that ADHD was present before
the comorbid psychiatric disorders, which all are
typically diagnosed in late adolescence and adult-
hood. Since the NorPD was established in 2004,
adults diagnosed and treated for ADHD only
before 2004 and not after will be undetected. How-
ever, ADHD was not understood as a disorder of
adulthood before the late 1990s, and during 1997–
2005, adults in Norway were only allowed to
receive medical treatment with central stimulants
after a thorough evaluation by one of three regio-
nal diagnostic committees (8). Further, some
ADHD patients will not receive medication
because of contraindications or other causes; these
patients are identified in the NPR, but only from
2008 and onwards. During 2008–2015, a total of
9346 (23.3%) adults with ADHD were registered
with ADHD in the NPR without receiving medica-
tion.
The NPR was the data source for defining psy-
chiatric comorbidities. In Norway, many psychi-
atric patients are followed in primary health care
after diagnosis, and treatment is established in sec-
ondary care, for example patients with bipolar dis-
order who are stable on medication. A recent
study from Sweden reported that almost 80% of
the most common mental disorders were treated in
primary care (57). For bipolar disorder, we there-
fore used the NorPD as an additional data source.
It is likely that patients with the more severe disor-
ders such as schizophrenia (31) and severe person-
ality disorders will likely have some contact with
specialist health care throughout life and should
therefore be captured by the NPR.
As discussed above, it may be argued that adults
with ADHD could more easily be diagnosed with
other psychiatric disorders because they are
already in contact with the health services (55).
This may be true, especially for depression and
anxiety in men, who in general have little contact
with the health service before old-age (54). How-
ever, adults with bipolar disorder, schizophrenia,
personality disorders and SUD are likely to be
referred to secondary health care also in the non-
ADHD population.
To conclude, a large proportion of both men
and women with ADHD have comorbid psychi-
atric disorders, and a considerable proportion of
anxiety, bipolar disorder, depression, schizophre-
nia, SUD and personality disorders in the
population can be attributed to an underlying
comorbid ADHD. The differences in prevalence of
anxiety, depression, bipolar and personality disor-
ders in adults with and without ADHD are larger
for women than for men. Clinicians treating
women with ADHD should be aware of these
comorbidities, to both detect the conditions and
offer early treatment if diagnosed. Similarly, the
possibility of a comorbid SUD or schizophrenia
spectrum disorder is particularly relevant when
treating men with ADHD. Importantly, clinicians
should also be aware of a possible underlying
ADHD when adults present with symptoms of
other psychiatric disorders. Identifying children
and adolescents with ADHD at earlier stages may
be an important preventive measure to reduce the
risk of future psychiatric comorbidity. This may be
particularly important in girls and women with
ADHD, who often have a lower degree of hyperac-
tivity and are therefore at an increased risk of
being undiagnosed in childhood, with a higher risk
of developing other psychiatric disorders as a pos-
sible consequence.
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Patterns of Psychiatric Comorbidity and Genetic
Correlations Provide New Insights Into
Differences Between Attention-Deficit/
Hyperactivity Disorder and Autism
Spectrum Disorder
Berit S. Solberg, Tetyana Zayats, Maj-Britt Posserud, Anne Halmøy, Anders Engeland,
Jan Haavik, and Kari Klungsøyr
ABSTRACT
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) share common
genetic factors but seem to have specific patterns of psychiatric comorbidities. There are few systematic studies on
adults; therefore, we compared psychiatric comorbidities in adults with these two neurodevelopmental disorders
using population-based data and analyzed their genetic correlations to evaluate underlying factors.
METHODS: Using data from Norwegian registries, we assessed patterns of psychiatric disorders in adults with ADHD
(n = 38,636; 2.3%), ASD (n = 7528; 0.4%), and both diagnoses (n = 1467; 0.1%) compared with the remaining adult
population (n = 1,653,575). We calculated their prevalence ratios (PRs) and differences using Poisson regression, also
examining sex-specific relations. Genetic correlations (rg) among ADHD, ASD, and the examined psychiatric disorders
were calculated by linkage disequilibrium score regression, exploiting summary statistics from relevant genome-wide
association studies.
RESULTS: For all psychiatric comorbidities, PRs differed between ADHD and ASD. Associations were strongest in
individuals with ADHD and ADHD1ASD for most comorbidities, in both men and women. The relative prevalence
increase of substance use disorder was three times larger in ADHD than in ASD (PRADHD, 6.2; 95% confidence in-
terval [CI], 6.1–6.4; PRASD, 1.9; 95% CI, 1.7–2.2; p , .001); however, the opposite was true for schizophrenia (PRASD,
13.9; 95% CI, 12.7–15.2; PRADHD, 4.4; 95% CI, 4.1–4.7; p , .001). Genetic correlations supported these patterns but
were significantly different between ADHD and ASD only for the substance use disorder proxies and personality traits
(p , .006 for all).
CONCLUSIONS: Adults with ADHD, ASD, or both ADHD and ASD have specific patterns of psychiatric comorbidities.
This may partly be explained by differences in underlying genetic factors.
Keywords: ADHD, ASD, Genetics, Psychiatric comorbidity, Schizophrenia, SUD
https://doi.org/10.1016/j.biopsych.2019.04.021
Attention-deficit/hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD) are highly heritable neuro-
developmental conditions and major contributors to human
suffering worldwide (1,2). There is emerging evidence of
polygenicity and environmental factors contributing to both
disorders (3,4). Genetic, epidemiological, and twin studies
show that ADHD and ASD often co-occur and share com-
mon underlying genetic factors (5–8), but with different
phenotypic characteristics. The shared genetic factors are
believed to affect the structure and function of molecular
networks in the brain, possibly involved in the etiology of
ADHD (9) and ASD (10).
Individuals with either ADHD or ASD have a 65% to 90%
risk of developing concomitant psychiatric disorders (11–13),
but with seemingly different patterns of comorbidity. Adults
with ASD present high rates of co-occurring anxiety, depres-
sion (13), bipolar disorder (BD), and schizophrenia spectrum
disorder (SCZ) (14–16), while adult ADHD is reported to co-
occur with anxiety disorder and major depressive disorder
(MDD) (17–19), BD (11,19–22), personality disorders (PDs)
(18,19,23), SCZ, (19,22,24,25), and substance use disorder
(SUD) (19,20,26).
ADHD and ASD share genetic factors with the above-
mentioned psychiatric disorders (27), and significant genetic
SEE COMMENTARY ON PAGE e25
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correlations between different phenotype-specific traits for
ADHD and ASD have been demonstrated (28).
Nonetheless, except for a couple of small clinical studies,
patterns of psychiatric comorbidities have not been system-
atically compared between adults with ASD or ADHD (29,30).
Further, previous studies have reported that children with both
ADHD and ASD may have more severe impairments than those
with ASD alone; however, comparable studies in adults are
lacking (31,32). Only one single population-based study has
directly compared individuals with ADHD alone, ASD alone, or
both ADHD and ASD with unaffected individuals, but this was
in a population too young to be diagnosed with adult-onset
psychiatric disorders (33).
We aimed at evaluating similarities and differences in psy-
chiatric comorbidity between ADHD and ASD in adulthood,
both clinically and genetically. Therefore, we compared the
prevalence of psychiatric disorders in adults with ADHD alone,
ASD alone, and both ADHD and ASD with adults without
ADHD or ASD and supplemented these analyses with the




We conducted cross-sectional analyses in a cohort of adults
by linking information from four nationwide, population-based
registries, all with compulsory notification: the Medical Birth
Registry of Norway, established in 1967 (34); the Norwegian
Prescription Database (NorPD) (35), established in 2004; the
Norwegian Patient Registry (NPR) (36), with data since 2008;
and the National Educational Database from Statistics Norway
(37,38) (see Supplement for more details).
Individual records from the registries were linked by means
of the unique national identification numbers, given to all in-
dividuals residing in the country. The Regional Ethics Com-
mittee in Norway approved the study (2011/2272). No informed
consent was required for the analyses, as the records were
anonymized. To guide the reporting of this study, we used the
Strengthening the Reporting of Observational Studies in
Epidemiology statement (39).
Study Population and Exposure Groups
The study included 1,701,206 individuals born in Norway be-
tween 1967 and 1997 who were alive and living in Norway in
2015, the year of data linkage. This population consists of in-
dividuals mainly of European descent, with 8.2% of births
registered to mothers from non-European countries by 2015.
We defined adults with ADHD only (ADHD) as those who were
dispensed ADHD medication at any time between 2004 and
2015 (NorPD) or had an ADHD diagnosis (ICD-10 code F90),
but no ASD diagnosis, registered in the NPR during 2008 to
2015, and who were 18 years of age or older. The ADHD
medications were methylphenidate, racemic amphetamine,
dexamphetamine, and atomoxetine. Individuals prescribed
central stimulants for narcolepsy were excluded (see
Supplement for details).
Adults with ASD only (ASD) were defined as individuals with
an ASD diagnosis (ICD-10 codes F84.0–11F84.51F84.8–9)
(40,41) who were 18 years of age or older, were registered in
the NPR during 2008 to 2015, and had no ADHD diagnosis.
Adults (18 years of age or older) with both ADHD and ASD as
defined above comprised the combined group (ADHD1ASD).
The remaining population included all adults who were
neither dispensed ADHD medication registered in the NorPD
nor had an ADHD or ASD diagnosis registered in the NPR.
Parents of adults with and without ADHD/ASD were also
identified through the Medical Birth Registry of Norway and
included in the analyses to account for parental factors asso-
ciated with ADHD, ASD, and other psychiatric disorders (e.g.,
sociodemographic factors, pregnancy-related factors, parental
psychiatric disorders) and relatedness.
Outcome Diagnoses
We studied the following major comorbid psychiatric disorders
typically diagnosed in late adolescence and adulthood (42), all
registered in the NPR, at 18 years of age or older: anxiety
disorders (ICD-10 codes F40–F42); MDD (F32–F33); BD (F30–
F31); PDs (F60–F61), with a separate analysis on antisocial
personality disorder (F60.2) (only included in the main analyses
because of a small number of cases); SCZ (F20–F29); and SUD
(F10–F19). For BD, we also included those individuals who
were dispensed lithium during 2004 to 2015, according to
NorPD.
Summary Statistics From Large-Scale Genome-
wide Association Studies
Summary statistics from the large-scale genome-wide asso-
ciation studies (GWASs) for the psychiatric disorders examined
(10,43–51) were downloaded from the LD Hub GWAS share
center (http://ldsc.broadinstitute.org/gwashare/) (52). To date,
no GWAS has examined the genetics of individuals diagnosed
with both ADHD and ASD. Combining the existing data from
individual GWASs on ADHD and ASD, respectively, would
result in associations heavily biased toward the larger study.
Thus, we analyzed ADHD and ASD separately.
As not all data are publicly available, and no large-scale,
well-powered GWASs were performed on all disorders exam-
ined, we used some proxy traits. Owing to the lack of adequate
genetic data on PDs, we combined the data from the five
GWASs on the five traits in the NEO Personality Inventory
(NEO) (neuroticism, extraversion, openness to experience,
agreeableness, and conscientiousness) (48,53) using the in-
verse variance method in METAL software (54). As all five NEO
personality traits were analyzed in same-sized samples, there
was no bias toward any of the traits. We also used the trait
“antisocial behavior” as a proxy for antisocial personality dis-
order (49). As proxies for SUD, we used smoking behavior (ever
smoked vs. never smoked) (51) and alcohol dependence (50).
In all analyses, we restricted the examined data to single
nucleotide polymorphisms of good imputation quality (INFO
$0.8), minor allele frequency $1% (common variation), and
the data were derived from individuals of European descent
only.
Statistical Analyses
We estimated prevalence ratios (PRs) using Poisson regres-
sion with robust standard errors (55) to examine the
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associations of ADHD, ASD, and ADHD1ASD with other
psychiatric disorders, using the remaining adult population as
reference. To adjust for potential confounders, we performed
two regression models, which included the following cova-
riates: 1) model I, which included birth year, maternal marital
status, maternal age and paternal age in years at delivery,
parents’ highest attained level of education at record linkage,
the individual’s gestational age in weeks, and the individual’s
gestational age- and sex-specific birth weight Z scores (56);
and 2) model II, which included covariates of model I and
mothers’ and fathers’ psychiatric diagnoses, including ADHD
or any other psychiatric diagnosis from the NPR from 2008 to
2015 (for details about the covariates, see footnotes beneath
the tables and figures and in the Supplement). To account for
correlations between siblings, we used mother’s identification
number as a cluster variable in the analyses.
Analyses were performed on the total sample and stratified
by sex. Our main analyses were based on the multiplicative
scale using relative effect measures; however, when assessing
sex differences, we supplemented the analyses with absolute
effect measures. For this, we estimated prevalence differences
of psychiatric disorders between men and women with and
without ADHD, ASD, or ADHD1ASD using predicted preva-
lence from a Poisson regression model with adjustment for
birth year (5-year periods). Significance of interaction by sex on
the multiplicative scale was evaluated by comparing the
Poisson regression models with and without the interaction
term (sex 3 ADHD) included, tested by likelihood ratio tests,
and significance of interaction by sex on the additive scale was
evaluated using relative excess risk due to interaction (57).
Two-sided tests with a significance threshold of p , .05
were employed in all analyses.
Analyses were carried out with SPSS version 22.0 (IBM
Corp., Armonk, NY) and STATA intercooled version 14
(StataCorp, College Station, TX) from November 3, 2017, to
March 13, 2019.
Genetic correlations (rg) were calculated using linkage
disequilibrium score regression, which quantifies the similarities
in genetic architecture between two traits by evaluating the
relationship between single nucleotide polymorphism associa-
tion strengths and genetic linkage disequilibrium (8). Owing to
sample overlap between the examined datasets, the correlations
were calculatedwithout constraining the intercept. To calculate if
the genetic correlations in the ADHD group were significantly
different from those in the ASD group, we applied the following
formula: rg12 rg2ffiffiffiffiffiffiffiffiffiffiffi
a2 1b2
p , where rg1 refers to the genetic correlation
between a comorbidity and ADHD, rg2 refers to the genetic
correlation between the same comorbid disorder and ASD, a
refers to SE of the rg1 estimate, and b refers to the standard error
of the rg2 estimate. The significance was calculated using a two-
tailed Z test. To account for multiple testing, Bonferroni correc-
tion was applied to the significant threshold of .05, bringing the
adjusted significance threshold to .00625.
Sensitivity Analyses
We conducted several sensitivity analyses to evaluate the
robustness of our results. We reran all the analyses 1)
excluding individuals with a diagnosis of intellectual disability,
2) excluding all with comorbid diagnoses of SCZ when
analyzing BD and SUD, 3) excluding all individuals with SUD
when analyzing SCZ, and 4) including only individuals who had
their psychiatric diagnosis registered at least twice in the NPR.
Missing values in covariates (6% for gestational age and birth
weight Z scores, ,1% for other variables) were handled by
listwise deletion in the main analyses. In the sensitivity ana-
lyses, we also used multiple imputation with chained equations
(58) to evaluate possible bias due to missing information in
gestational age when adjusting for covariates. The outcome
variables, all specified covariates, and also birth weight,
maternal pre-eclampsia, and mother’s chronic diseases (yes/
no) were used for this information.
RESULTS
Study Population
Among the 1,701,206 individuals included in the study, we
identified 38,636 adults (2.3% of the population; 45% women)
with ADHD, 7528 adults (0.4%; 27.9% women) with ASD, 1467
adults (0.1%; 28.8% women) with ADHD1ASD, and 1,653,575
adults (97.2%; 49% women) in the remaining population. In
2015, the mean ages of individuals in the ADHD, ASD, and
ADHD1ASD groups were 31, 26, and 27 years of age,
respectively, compared with 33 years of age in the remaining
population (Table 1). Among parents, significantly more
mothers of individuals with ASD and ADHD1ASD had the
highest level of education compared with the ADHD group and
the remaining population, likely explained by the mothers of
individuals with ASD/ADHD1ASD having been born later in our
study period, in a time during which higher education was
more common. In addition, being diagnosed with at least one
psychiatric disorder was more prevalent among parents of
individuals in all exposure groups, compared with the
remaining population (Table 1).
Psychiatric Comorbidity in Adults With ADHD, ASD,
or ADHD1ASD
Comorbid psychiatric disorders were 2 to 14 times more
common in adults with ADHD, ASD, or ADHD1ASD than in the
remaining population (Table 2). Overall, the PRs differed
significantly between adults with ADHD and ASD for all psy-
chiatric disorders studied. Relative to the remaining popula-
tion, the association with BD was the strongest and the
association with MDD was the weakest in adults with ADHD
(PRBD, 7.1; 95% confidence interval [CI], 6.8–7.4; PRMDD, 3.7;
95% CI, 3.6–3.8), while the association with SCZ was the
strongest and the association with SUD was the weakest in
adults with ASD (PRSCZ, 13.9; 95% CI, 12.7–15.2; PRSUD, 1.9;
95% CI, 1.7–2.2) (Table 2, model II). The associations with
anxiety disorders, BD, MDD, PDs, and SUD were significantly
stronger in adults with ADHD than in adults with ASD (p , .001
for all), with SUD revealing a particularly pronounced difference
(PRADHD, 6.2 vs. PRASD, 1.9). The association with SCZ, how-
ever, was stronger in adults with ASD than in adults with ADHD
(PRASD, 13.9 vs. PRADHD, 4.4; p , .001).
In the ADHD1ASD group, the PRs ranged from 3.6 for MDD
(95% CI, 3.2–4.0) to 12.5 for SCZ (95% CI, 10.3–15.1) (Table 2,
model II). For all disorders, except MDD and SUD, associations
with ADHD1ASD were significantly stronger than for those
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with ADHD. For SCZ, associations with ADHD1ASD and ASD
were similar, and both were significantly stronger than asso-
ciations with ADHD (PRADHD1ASD, 12.5; 95% CI, 10.3–15.1;
PRASD, 13.9; 95% CI, 12.7–15.2; PRADHD, 4.4; 95% CI,
4.1–4.7; p , .001).
Sex-Specific Results
When stratifying on sex, patterns of psychiatric comorbidity
corresponded with those in the total sample (Figure 1;
Supplemental Tables S2, S3). In both men and women, PR
estimates for SCZ were significantly larger in ASD or
Table 1. Sample Characteristics of the 1,701,206 Adults in the Study Population, All Born From 1967 to 1997 and Followed
Until 2015
Variable ADHD ASD ADHD1ASD Remaining Population
Population 38,636 (2.3) 7528 (0.4) 1467 (0.1) 1,653,575 (97.2)
Women 17,393 (45.0), p , .001a 2099 (27.9), p = .491b 422 (28.8), p , .001c 809,962 (49.0), p , .001d
Male/Female Ratio 1.22 2.58 2.48 1.04
Age in 2015, Years 31.3 6 8.3, p , .001a 26.2 6 7.9, p = .99b 26.8 6 7.1, p , .001c 33.2 6 9.3, p , .001d
Maternal Age at Birth p , .001a p , .001b p , .001c p , .001d
,20 years 4417 (11.4) 372 (4.9) 107 (7.3) 112,674 (6.8)
20–24 years 13,587 (35.2) 1936 (25.7) 435 (29.7) 498,264 (30.1)
25–29 years 11,865 (30.7) 2539 (33.7) 525 (35.8) 575,743 (34.8)
30–34 years 6144 (15.9) 1747 (23.2) 279 (19.0) 327,637 (19.8)
35–39 years 2215 (5.7) 774 (10.3) 102 (7.0) 116,139 (7.0)
401 years 408 (1.1) 160 (2.1) 19 (1.3) 23,118 (1.4)
Paternal Age at Birth p , .001a p , .001b p , .001c p , .001d
,20 years 1054 (2.7) 75 (1.0) 21 (1.4) 24,546 (1.5)
20–24 years 9013 (23.3) 1093 (14.5) 267 (18.2) 302,939 (18.3)
25–29 years 12,941 (33.5) 2242 (29.8) 484 (33.0) 563,896 (34.1)
30–34 years 8728 (22.6) 2120 (28.2) 392 (26.7) 432,678 (26.2)
35–39 years 4086 (10.6) 1154 (15.3) 182 (12.4) 207,833 (12.6)
40–44 years 1621 (4.2) 519 (6.9) 78 (5.3) 76,947 (4.7)
45–49 years 489 (1.3) 171 (2.3) 25 (1.7) 24,796 (1.5)
501 years 183 (0.5) 70 (0.9) 3 (0.2) 8741 (0.5)
Missing 521 (1.4) 84 (1.1) 15 (1.0) 11,199 (0.7)
Maternal Marital Statusd p , .001a p , .007b p = .016c p , .001d
Single 6483 (16.8) 909 (12.1) 225 (15.3) 151,975 (9.2)
Married/cohabiting 31,122 (80.6) 6508 (86.5) 1220 (83.2) 1,482,685 (89.7)
Other 924 (2.4) 96 (1.3) 20 (1.4) 16,154 (1.0)
Missing 107 (0.3) 15 (0.2) 2 (0.1) 2761 (0.2)
Maternal Education Status p , .001a p = .169b p , .001c p , .001d
Low 13,498 (34.9) 1904 (25.3) 394 (26.9) 430,874 (26.1)
Middle 16,478 (42.7) 3022 (40.1) 583 (39.7) 768,773 (46.5)
High 8415 (21.8) 2565 (34.1) 488 (33.3) 447,380 (27.1)
Missing 245 (0.6) 37 (0.5) 2 (0.1) 6548 (0.4)
Paternal Education Status p , .001a p , .001b p , .001c p , .001d
Low 12,501 (32.4) 1639 (21.8) 388 (26.5) 381,154 (23.1)
Middle 18,626 (48.2) 3486 (46.3) 694 (47.3) 834,541 (50.5)
High 6475 (16.8) 2237 (29.7) 352 (24.0) 414,399 (25.1)
Missing 1034 (2.7) 166 (2.2) 33 (2.3) 23,481 (1.4)
Maternal Psychiatric Disorder p = .073a p , .001b p = .001c p , .001d
None 28,140 (72.8) 5557 (73.8) 1009 (68.8) 1,432,294 (86.6)
Paternal Psychiatric Disorder p , .001a p = .010b p = .492c p , .001d
None 31,478 (82.7) 6289 (84.7) 1189 (82.0) 1,479,367 (90.2)
Values are n (%) or mean 6 SD.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
aDifference between the ADHD and ASD cases (Pearson chi-square test and t test for equality of means).
bDifference between the ASD and ADHD1ASD cases (Pearson chi-square test and t test for equality of means).
cDifference between the ADHD and ADHD1ASD cases (Pearson chi-square test and t test for equality of means).
dDifference between cases relative to the comparison population (Pearson chi-square test and t test for equality of means).
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ADHD1ASD than in ADHD, while for SUD, estimates were
significantly larger for ADHD or ADHD1ASD than for ASD. For
anxiety disorders, the PR estimates were significantly larger in
men than in women for all exposure groups, and for SCZ, the
PR was significantly larger in women with ASD than in men
with ASD.
When evaluating associations and interactions on the ad-
ditive scale, sex differences were more pronounced, and the
prevalence difference estimates were significantly different for
all the disorders in women and men with ADHD but for only
three disorders in men and women with ASD (Figure 2;
Supplemental Table S4). Further, the associations were
reversed, and prevalence of most psychiatric disorders
increased more in women than in men in all exposure groups
except SUD and SCZ, in which men in all exposure groups
showed the highest prevalence increase.
Genetic Correlations
As shown in Figure 3, the patterns of genetic correlations (rg)
were similar to those of the PRs for psychiatric comorbidities
based on the epidemiological data. The two proxies for SUD
revealed significantly stronger correlations with ADHD than
with ASD (Figure 3, right panel; Supplemental Table S5). For
Anxiety MDD PD
Schizophrenia SUD BD








































Figure 1. Prevalence ratios of psychiatric disorders in adults with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), or
ADHD1ASD relative to the remaining population, by sex. Log scale, 95% confidence interval, error bars. Adjusted for birth year (5-year groups, from 1967 to
1997, with 1967–1973 as the reference), maternal marital status (single, married/cohabiting [reference], other), maternal and paternal education (low [,10
years], middle [10–12 years] and high [.12 years] [reference]), maternal age (,20, 20–24, 25–29 [reference], 30–34, 35–39, 401 years of age) and paternal age
(,20, 20–24, 25–29, 30–34 [reference], 35–39, 40–44, 45–49, 501 years of age) at delivery, gestational age (,28, 28–31, 32–34, 35–36, 37–41 [reference], 421
weeks of age), gestational age- and sex-specific birth weight Z scores (,22.0; 22.0 to 20.51; 20.5 to 0.5 [reference]; 0.51 to 2.0; 2.011), and maternal and
paternal psychiatric disorders (yes/no). BD, bipolar disorder; MDD, major depressive disorder; PD, personality disorders; schizophrenia, schizophrenia
spectrum disorder; SUD, substance use disorder.
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SCZ, the rg estimate for ASD was almost twice as large as that
for ADHD (rg(ASD1SCZ): 0.211 [SE: 0.048, p , .0001];
rg(ADHD1SCZ): 0.127 [SE: 0.036, p = .0004]), but this difference
was not statistically significant (p = .16). The differences in
genetic correlations between ADHD and ASD with the exam-
ined comorbid disorders were statistically significant only for
the SUD proxies and for the NEO personality dimensional traits
(Supplemental Table S5).
Sensitivity Analyses
When we excluded individuals with intellectual disability, the
results changed only for ASD, in which the PR for SCZ
increased slightly (PRcrude, 15.1; 95% CI, 13.9–16.4; PRsensitivity,
16.5; 95% CI, 15.1–18.1). For the ADHD and the ADHD1ASD
groups, there were no substantial changes. All the other
sensitivity analyses yielded results that were very similar to
those of the main analyses (Supplemental Tables S6, S7).
DISCUSSION
In this first nationwide, population-based study combining
epidemiological data on adults with ADHD only, ASD only, or
both ADHD and ASD, together with corresponding genetic
data, we found different patterns of psychiatric comorbidities
between the groups, overall and also when stratifying by sex.
These patterns were also reflected in the genetic correlations;
however, only proxies for two of the six traits showed a sig-
nificant difference between ADHD and ASD. We also found
that adults with both ADHD and ASD have severe additional




























































Figure 2. Prevalence difference of psychiatric disorders in adults with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD),
ADHD1ASD relative to the remaining population, by sex. Prevalence difference, 95% confidence interval, error bars, analog scale. Adjusted for birth year
(5-year groups, from 1967 to 1997). BD, bipolar disorder; MDD, major depressive disorder; PD, personality disorders; schizophrenia, schizophrenia spectrum
disorder; SUD, substance use disorder.
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When comparing ADHD and ASD in our epidemiological
data, we observed significant differences in the associations
with all psychiatric comorbidities examined, with individual
estimates being consistent with previous studies
(11–13,15,24,30–32). The most marked differences were found
for SCZ and SUD, in which SCZ was more common in adults
with ASD and SUD was more common in adults with ADHD.
Associations with anxiety disorders, BD, and PDs were
strongest in adults with both ADHD and ASD, indicating that
this group of adults has more severe impairments than those
with ADHD or ASD only (59). This is supported by previous
studies in children (32,60). Further, we found that adults with
both ADHD and ASD had a similar increase in risk for SCZ as
that for adults with ASD only, which, as far as we know, has not
been shown before. To our knowledge, only one other
population-based study reported the prevalence of psychiatric
disorders among individuals with ADHD, ASD, or ADHD1ASD
compared with unaffected individuals in the same population
(33). However, this population was young (mean age ranging
from 13.6 to 18.3 years) and had not reached the typical age of
onset for most psychiatric disorders (42). The reported esti-
mates were, therefore, likely to be biased.
With regard to the genetic correlations, the patterns were
similar to those we observed in the epidemiological data, and
two—the SUD proxies and NEO personality traits—revealed
significant differences in their correlations with ADHD and
ASD. The genetic correlation (rg) between ADHD and ASD has
been estimated to be 0.36 (10), indicating shared genetic
etiology between them. Nonetheless, it is conceivable that
their polygenic architecture is still different, as supported by
our epidemiological observation of significantly different pat-
terns of comorbidities between these two disorders. It has also
been shown that individuals with various clinical manifesta-
tions of ASD reveal distinct loads of genetic variants associ-
ated with this disorder (10,61).
Etiological similarities, as well as differences between ADHD
and ASD, can be further and more specifically evaluated by
examining their symptom dimensions, each of which may have
independent and different explanatory values for the clinical
diagnoses of ADHD, ASD, and their comorbidities. Ghirardi
et al. (28), for example, have reported that the symptoms of
hyperactivity/impulsivity (ADHD) show different levels of ge-
netic correlation with symptoms of ASD (e.g., a strong genetic
correlation with repetitive and restricted behaviors [ASD] and a
weak correlation with social interaction and communication).
Our current diagnostic criteria are based on clinically observed
aggregates of symptoms but may not relate to distinct un-
derlying biological pathways. Hence, well-powered GWASs on
clearly defined specific psychiatric phenotypes and narrower
symptom domains are needed to uncover the biological
mechanisms underlying the multifaceted etiologies of ADHD
and ASD.
Apart from genetics, the observed differences in patterns of
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Figure 3. (Left panel) The pattern of prevalence ratios of psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD) (n = 38,636) or
autism spectrum disorder (ASD) (n = 7528) observed in this study and (right panel) genetic correlations (rg) calculated from genome-wide association studies.
(Left panel) Prevalence ratio, model II, log-scale, 95% confidence interval, error bars. Adjusted for birth year (5-year groups, from 1967 to 1997, with 1967–1973
as the reference), maternal marital status (single, married/cohabiting [reference], other), maternal and paternal education (low [,10 years], middle [10–12 years]
and high [.12 years] [reference]), maternal age (,20, 20–24, 25–29 [reference], 30–34, 35–39, 401 years of age) and paternal age (,20, 20–24, 25–29, 30–34
[reference], 35–39, 40–44, 45–49, 501 years of age) at delivery, gestational age (,28, 28–31, 32–34, 35–36, 37–41 [reference], 421 weeks of age), gestational
age- and sex-specific birth weight Z scores (,22.0; 22.0 to 20.51; 20.5 to 0.5 [reference]; 0.51 to 2.0; 2.011), and maternal and paternal psychiatric dis-
orders (yes/no). (Right panel) Genetic correlations, rg, linear scale, SE bars, with “Ever vs Never Smoked” and “Alcohol Dependence” as proxies for substance
use disorder, and “NEO–5–Personality Traits” as proxy for personality disorder.
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by diagnostic factors. Diagnosing psychiatric comorbidities in
adults with ASD is difficult, as many diagnostic tools are not
customized for these individuals (31,62). In addition, clinicians
may not look for additional psychiatric disorders in ASD pa-
tients and explain their symptoms as part of the underlying
ASD (32), i.e., diagnostic overshadowing (63). Further, on a
more psychological level, even if individuals with ADHD or ASD
often experience peer rejection and relational problems (64,65),
individuals with ASD are diagnostically defined by their strug-
gle to communicate and hence are less able to communicate
their problems because of their large impairments (66,67). This
may contribute to a lower level of diagnosed psychiatric
comorbidities in individuals with ASD.
The sex differences in risk of psychiatric comorbidities were
different among adults with ADHD and ASD, on both the
relative and absolute scales. The present findings for adults
with ADHD are also presented in our previous publication (19)
and were confirmed by a recent Swedish study (68). Sex dif-
ferences are strongly dependent on the scale used for ana-
lyses, with stronger associations for most psychiatric
comorbidities in men than in women on the relative scale and
stronger associations in women than in men on the absolute
scale. This may be explained by the lower prevalence in psy-
chiatric disorders among men than women in the reference
group, which has a profound influence on the relative effect
measures but not on the risk differences. We suggest that the
smaller sex differences observed in adults with ASD than
ADHD may partly be explained by the larger male/female ratio
in adults with ASD and partly by women with ASD struggling
more to communicate internalizing symptoms than women
with ADHD (69,70).
The behavioral patterns in the individuals of the two
phenotypically different disorders also lead to different in-
teractions with their environments. The differences in the as-
sociations with SUD between ADHD and ASD may partly be
due to the ADHD-associated novelty seeking and impulsive
behavior, increasing the risk of developing SUD to a larger
degree in ADHD than in ASD, in which a rigid and norm-abiding
behavior, with limited social contact, may be relatively pro-
tective (30,71,72). Thus, both genetic and environmental risk
factors, as well as their interactions, may alter the expression
of genes and affect the structure and function of molecular
networks in the brain, thereby modifying the risk of ADHD and
ASD (32).
Strengths and Limitations
To our knowledge, this is the largest population-based study
comparing psychiatric comorbidity in adults with ADHD, ASD,
or both ADHD and ASD conducted so far. The analyses were
also stratified according to sex and included genetic correla-
tions in the interpretation. We used data from nationwide,
population-based registries with compulsory notification, thus
reducing selection bias to a minimum. As our patient groups
were large enough to allow us to study individuals with either
ADHD alone or ASD alone, or both ADHD and ASD, we were
able to study differences between more homogeneous groups.
We designed our study specifically to examine an adult
population, allowing all participants to reach the typical age of
diagnosis of the conditions investigated (42). Notably, this
study covers the first birth cohort for which ASD became
prevalent enough in adulthood to enable such a study to be
performed.
In Norway, formal diagnoses of ASD and ADHD, and
pharmacological treatment of ADHD, are always based on
clinical evaluation by specialists. Thus, identification of ADHD
and ASD cases was not based solely on symptom scores or
self-reports. We chose to identify the ADHD cases either by a
dispensed prescription of ADHD medication from the NorPD or
by an ADHD diagnosis from the NPR, similar to other Scan-
dinavian studies (22,73–75). ASD, BD, and SCZ diagnoses in
the NPR have been validated with good results (36,76), sug-
gesting acceptable validity for other NPR-registered psychi-
atric diagnoses as well. However, we cannot exclude a
possible misdiagnosis of SCZ and ASD. Our definition of BD
was also based on dispensed lithium, a medication mainly
used for treating BD.
Limitations include the fact that our analyses were cross-
sectional and based on data registered from 2004 to 2015
(NorPD) and from 2008 to 2015 (NPR), preventing the exami-
nation of temporal relations. However, as ADHD and ASD are
defined as neurodevelopmental disorders with an onset in
childhood, we assume that they were present before the co-
morbid psychiatric disorders, all typically diagnosed in late
adolescence and adulthood (42).
Up to 2013, an ASD diagnosis would preclude a diagnosis
ADHD according to the DSM-IV and ICD-10 (77,78). This may
have affected the diagnostic procedures and hindered clini-
cians from diagnosing both disorders if the criteria for ASD
were fulfilled. However, clinical practice has not adhered
strictly to these criteria, as growing evidence supported the
importance of diagnosing both conditions when present to
provide the best treatment (31).
Further, it may be argued that adults with ADHD or ASD
could more easily get other psychiatric diagnoses because
they are already in touch with the health care system (79).
However, all adults with severe psychiatric disorders are likely
to be in touch with secondary health care throughout life, in-
dependent of underlying neurodevelopmental disorders (80).
With regard to the genetic correlations, it is important to
note that their estimations are highly dependent on the sample
size of the utilized GWAS. In addition, because there are no
large-scale GWASs with freely available summary statistics for
some of the examined comorbidities, proxy phenotypes were
examined. Furthermore, patients’ comorbidities are not always
taken into account in the genetic studies, although individuals
with known combined ADHD and ASD were excluded from
some studies (43). Currently, psychiatric genetics are lacking
GWASs on patients with comorbidities or with specific symp-
toms of psychiatric disorders, which limits our ability to
examine the genetic variability that may be responsible for the
diverse clinical landscape of psychiatric disorders.
Conclusions
In conclusion, our study provides robust and representative
estimates of differences in psychiatric comorbidities among
adults diagnosed with ADHD, ASD, or ADHD1ASD. With the
results from analyses of genetic correlations, this finding
contributes to our understanding of these disorders as being
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distinct neurodevelopmental disorders with partly shared
common genetic factors. Clinicians should be aware of the
overall high level of comorbidity in adults with ADHD, ASD, or
ADHD1ASD and of the distinct patterns of psychiatric
comorbidities to detect these conditions and offer early treat-
ment. It is also important to take into account the observed sex
differences. The distinct comorbidity patterns may provide
further information regarding etiologic research on biological
mechanisms underlying the pathophysiology of these neuro-
developmental disorders.
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